<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia - Martí‐Carvajal, AJ - 2015 | Cochrane Library</title> <meta content="Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia - Martí‐Carvajal, AJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008562.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia - Martí‐Carvajal, AJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008562.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008562.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia" name="citation_title"/> <meta content="Arturo J Martí‐Carvajal" name="citation_author"/> <meta content="Iberoamerican Cochrane Network" name="citation_author_institution"/> <meta content="arturo.marti.carvajal@gmail.com" name="citation_author_email"/> <meta content="Vidhu Anand" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Ivan Solà" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD008562.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/06/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008562.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008562.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008562.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Anticoagulants [*therapeutic use]; Chronic Disease; Dermatan Sulfate [therapeutic use]; Disseminated Intravascular Coagulation [*drug therapy]; Leukemia [blood, *complications]; Protein C [therapeutic use]; Randomized Controlled Trials as Topic; Thrombomodulin [therapeutic use]; Tranexamic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008562.pub3&amp;doi=10.1002/14651858.CD008562.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="wbKFI7vu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008562\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008562\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008562.pub3",title:"Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia",firstPublishedDate:"Jun 24, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008562.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008562.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008562.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008562.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008562.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008562.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008562.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008562.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008562.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008562.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3655 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008562.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/appendices#CD008562-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information#CD008562-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Arturo J Martí‐Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information#CD008562-cr-0003">Vidhu Anand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information#CD008562-cr-0004">Ivan Solà</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information/en#CD008562-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 June 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008562.pub3">https://doi.org/10.1002/14651858.CD008562.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008562-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008562-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008562-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008562-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008562-abs-0001" lang="en"> <section id="CD008562-sec-0001"> <h3 class="title" id="CD008562-sec-0001">Background</h3> <p>Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic intravascular activation of coagulation, leading to deposition of fibrin in the bloodstream. It may occur in patients with acute and chronic leukemia and is particularly associated with acute promyelocytic leukemia (a subtype of acute myeloid leukemia). </p> </section> <section id="CD008562-sec-0002"> <h3 class="title" id="CD008562-sec-0002">Objectives</h3> <p>To assess the clinical benefits and harms of any pharmacological intervention for treating DIC in patients with acute or chronic leukemia. </p> </section> <section id="CD008562-sec-0003"> <h3 class="title" id="CD008562-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2015, Issue 05), MEDLINE (1946 to 7 May 2015), LILACS (1982 to 7 May 2015) and African Index Medicus (7 May 2015). There was no language restrictions. We sought additional randomized controlled trials (RCTs) from the World Health Organization International Clinical Trials Registry Platform and the reference lists of primary studies identified. </p> </section> <section id="CD008562-sec-0004"> <h3 class="title" id="CD008562-sec-0004">Selection criteria</h3> <p>RCTs assessing the clinical benefits and harms of interventions for treating DIC in patients with acute and chronic leukemia. </p> </section> <section id="CD008562-sec-0005"> <h3 class="title" id="CD008562-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed trial selection, 'Risk of bias' assessment and data extraction. Primary outcomes were overall mortality, in‐hospital mortality from any cause (15‐day and 30‐day) and adverse events. </p> </section> <section id="CD008562-sec-0006"> <h3 class="title" id="CD008562-sec-0006">Main results</h3> <p>In this Cochrane Review update we did not include any new RCT compared with the first review version. Accordingly, four RCTs (388 participants) met the inclusion criteria. These trials evaluated the human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate. Included trials reported data on mortality and bleeding. The studies were conducted in Japan, Italy and the Netherlands. We classified the included trials as: 1) including patients with or without leukemia which did not report data for the leukemia subgroup (366 participants); and 2) only including patients with leukemia (22 participants). Overall, the risk of bias of the included trials was high, since the trial authors did not provide a detailed description about trial design and execution. </p> <p>According to the GRADE recommendations, we judged the overall quality of the body of evidence for all prefixed outcomes as 'very low', due to methodological limitations and very small sample size. </p> <p>One trial, including 10 participants with leukemia and comparing dermatan sulphate with heparin, reported no deaths during trial treatment. </p> <p>In terms of bleeding data, we were unable to pool results from two studies that were only conducted with leukemia patients due to the inconsistency in the measurement and reporting of this outcome. One trial, including 12 participants with leukemia, found very low quality evidence that tranexamic acid can reduce the cumulative hemorrhagic score in participants compared with those assigned to placebo (P = 0.0015, very low quality evidence). On the contrary, there is no evidence that dermatan sulphate compared with placebo reduces new events of hemorrhagic diathesis (1/5 (20%) versus 2/5 (40%); RR 0.50; 95% CI 0.06 to 3.91; P = 0.51, very low quality evidence). </p> <p>No thromboembolic complications were reported in either trial that included patients with leukemia only (very low quality evidence). The safety profile was inconclusive. </p> <p>The included trials did not assess overall mortality, resolution of respiratory failure, renal failure or shock. </p> </section> <section id="CD008562-sec-0007"> <h3 class="title" id="CD008562-sec-0007">Authors' conclusions</h3> <p>Due to a lack of new RCTs, our conclusions in this Cochrane Review update are the same as the previous review version. We included four RCTs which reported mortality and bleeding data. It is not possible to determine whether human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate are effective or harmful for patients presenting with DIC related to acute or chronic leukemia. The quality of the evidence was low to very low. Therefore, prescription of these interventions for treating DIC in patients with acute and chronic leukemia can neither be supported nor rejected, unless new evidence from a large high‐quality trial alters this conclusion. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008562-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008562-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008562-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008562-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008562-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008562-abs-0003" lang="en"> <h3>Drug therapy for treating systemic intravascular activation of coagulation in patients with leukemia </h3> <p><b>Review question</b> <br/> We reviewed the clinical benefits and harms of anticoagulant and antifibrinolytic therapy for treating disseminated intravascular coagulation (DIC) in patients with acute or chronic leukemia. </p> <p><b>Background</b> <br/> DIC is a thrombo‐hemorrhagic complication (involving blood clotting or bleeding) characterized by deposition of fibrin (a fibrous protein) in the bloodstream, which occurs in the course of various diseases including acute and chronic leukemia and is particularly associated with acute promyelocytic leukemia (a subtype of acute myeloid leukemia). DIC is never considered as an isolated clinical entity and represents a hematological emergency. Therefore, DIC requires treatment and resolution of the underlying disease in addition to other approaches, such as antibiotic therapy, replacement of blood products and fluid therapy, which are considered 'primary' or 'conventional care' interventions. DIC is accompanied by hyperfibrinolysis (increased dissolution of blood clots) and reduction of natural anticoagulants (proteins of the coagulation cascade). Hence, pharmacological interventions such as tranexamic acid (an antifibrinolytic agent) and heparin (an anticoagulant) have been used for treating patients with this acquired disorder. However, this practice is not considered as standard care and there is a lot of controversy about its clinical benefits. </p> <p><b>Study characteristics</b> </p> <p>We included four trials that had a limited number of patients (388) and assessed four different interventions: human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate with heparin or placebo. Two trials included patients either with or without leukemia. The other two trials only included patients with leukemia. The studies were published between 1989 and 2007, and were conducted in Japan, Italy and the Netherlands. All trials have a high risk of bias. </p> <p><b>Key results</b> </p> <p>There were no deaths reported in a trial comparing dermatan sulphate with heparin. Two small trials which included patients with leukemia only (22 participants) reported bleeding data. These results were not compiled due to inconsistency in the measurement and reporting of that outcome. One trial found very low quality evidence that tranexamic acid compared with placebo reduces bleeding in leukemia patients. On the contrary, there is no evidence that dermatan sulphate compared with placebo reduces new events of hemorrhagic diathesis in patients with leukemia. Saftey profile is inconclusive. No thromboembolic complications were reported in both the trials. </p> <p>These trials did not report overall mortality, resolution of respiratory failure, renal failure and shock. </p> <p>Accordingly, the clinical benefits and harms of the human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate are unknown in this population. </p> <p><b>Quality of evidence</b> </p> <p>The confidence in the results of this review is very low. The studies have limitations in the way they were designed and executed. Moreover, the limited number of patients included in the studies led to imprecise results. Well conducted larger studies will provide more information about the effect of human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate for treating DIC in patients with acute or chronic leukemia. </p> <p>This plain language summary is current as of 7 May 2015.</p> <p>Search date: 7 May 2015</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008562-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008562-sec-0101"></div> <h3 class="title" id="CD008562-sec-0102">Implications for practice</h3> <section id="CD008562-sec-0102"> <p>This updated Cochrane Review has no new RCTs included. Therefore, the implications for clinical practice from <a href="./references#CD008562-bbs2-0139" title="Marti‐CarvajalAJ , SimancasD , CardonaAF . Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2] ">Marti‐Carvajal 2011</a> still apply. </p> <p>We included four small RCTs of low methodological quality. It is not possible to determine whether human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate are effective or harmful to patients presenting with DIC related to acute or chronic leukemia, due to the inconsistency in the measurement and reporting of mortality and bleeding data. For the same reason, we were unable to pool results from these trials. Therefore, prescription of these interventions for treating DIC in patients with acute and chronic leukemia can neither be supported nor rejected, unless new evidence from a large high‐quality trial alters this conclusion. </p> </section> <h3 class="title" id="CD008562-sec-0103">Implications for research</h3> <section id="CD008562-sec-0103"> <p>Further well‐designed, high power RCTs are necessary to evaluate the role of pharmacological interventions for treating DIC in patients with acute and chronic leukemia effectively. Future trials should include the following outcomes: mortality from any cause (15‐day and 30‐day in‐hospital), overall mortality, hemorrhagic diatheses, resolution of respiratory failure, renal failure, shock and safety. The definition of bleeding should be standardized in these patients. </p> <p>This review update suggests that potential trials should be planned using Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (<a href="./references#CD008562-bbs2-0062" title="ChanAW , TetzlaffJM , GøtzschePC , AltmanDG , MannH , BerlinJA , atal . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ2013;346:e7586. [PUBMED: 23303884] ">Chan 2013</a>) and reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement for improving the quality of reporting of efficacy and of harms in clinical research (<a href="./references#CD008562-bbs2-0061" title="CalvertM , BlazebyJ , AltmanDG , RevickiDA , MoherD , BrundageMD . Reporting of patient‐reported outcomes in randomized trials: the CONSORT PRO extension. JAMA2013;309(8):814‐22. [PUBMED: 23443445] ">Calvert 2013</a>; <a href="./references#CD008562-bbs2-0124" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine2010;152(11):726‐32. [PUBMED: 20335313 ] ">Schulz 2010</a>). The trials should be conducted according to the PCORI recommendations (<a href="./references#CD008562-bbs2-0117" title='Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: "Our questions, our decisions: Standards for patient‐centered outcomes research". http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 1 April 2013):1‐61. '>PCORI 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008562-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008562-sec-0015"></div> <div class="table" id="CD008562-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Human activated protein C versus heparin for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Human activated protein C versus heparin for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> human activated protein C<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Human activated protein C</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (108 to 388) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> <br/> (0.27 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (2 to 206) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> <br/> (0.05 to 5.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> <br/> (0 to 126) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.06</b> <br/> (0 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Indirectness: trial included patients with or without leukemia; and this outcome was not discriminated by type of patients.<br/> <sup>2</sup>Limitations in execution: large loss (21.3%) to follow up could bias the reported estimates. Trial authors reported no reasons for attrition could bias the reported estimates.<br/> <sup>3</sup>Imprecision: low sample size (104 participants and 32 events) resulting in wide 95% CIs.<br/> <sup>4</sup>Imprecision: low sample size (107 participants and 3 events) resulting in wide 95% CIs.<br/> <sup>5</sup>Imprecision: low sample size (132 participants and 8 events) resulting in wide 95% CIs.<br/> <sup>6</sup>Quality of evidence rated and effect estimates obtained for aggravation of bleeding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008562-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Recombinant human soluble thrombomodulin compared with heparin for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Recombinant human soluble thrombomodulin compared with heparin for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> recombinant human soluble thrombomodulin<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Recombinant human soluble thrombomodulin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> <br/> (139 to 349) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.54 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> <br/> (27 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.35 to 2.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Indirectness: trial included patients with or without leukemia; and this outcome was not discriminated by type of patients.<br/> <sup>2</sup>Imprecision: low sample size (227 participants and 54 events) resulting in wide 95% CIs.<br/> <sup>3</sup>Imprecision: low sample size (231 participants with 17 events) resulting in wide 95% CIs.<br/> <sup>4</sup>Author trials measured this outcome either clinical benefit or harm.<br/> <sup>5</sup>Trial authors reported P = 0.0271 for "disappearance rate of bleeding symptoms at day 7". Results were not discriminated according patients with or without leukemia. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008562-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tranexamic acid compared with placebo for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tranexamic acid compared with placebo for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> tranexamic acid<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported no thromboembolic events over course of trial</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial reported no number of events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Limitations in design and execution: insufficient information about the random sequence generation, allocation concealment and blinding. High risk for reporting bias.<br/> <sup>2</sup>Imprecision: low sample size (12 participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008562-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Dermatan compared with heparin for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dermatan compared with heparin for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> dermatan<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Dermatan</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> <br/> Follow‐up: 9 and 18 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial reported no death during study treatment.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 9 and 18 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It did not report information on safety explicitly.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 9 and 18 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> <b>(24 to 1000)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.5</b> <br/> <b>(0.06 to 3.91)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Limitations in design and execution: insufficient information about the random sequence generation, allocation concealment, and blinding. High risk for reporting bias.<br/> <sup>2</sup>Imprecision: low sample size (10 participants) and low rate of events (3 in total) resulting in wide 95% CIs. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008562-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008562-sec-0016"></div> <section id="CD008562-sec-0017"> <h3 class="title" id="CD008562-sec-0017">Description of the condition</h3> <p>Hemostasis (blood coagulation) is a self‐defense system to prevent death secondary to massive bleeding after a blood vessel injury (<a href="./references#CD008562-bbs2-0064" title="ChuAJ . Biochemical strategies to anticoagulation: a comparative overview. Current Vascular Pharmacology2004;2(3):199‐228. [PUBMED: 15320820] ">Chu 2004</a>). Blood coagulation and the inflammatory process are interrelated as part of the innate host defense mechanism and form part of the argument for the hemostasis theory (<a href="./references#CD008562-bbs2-0076" title="EngelmannB , MassbergS . Thrombosis as an intravascular effector of innate immunity. Nature Reviews. Immunology2013;13(1):34‐45. [PUBMED: 23222502] ">Engelmann 2013</a>; <a href="./references#CD008562-bbs2-0132" title="van derPollT , HerwaldH . The coagulation system and its function in early immune defense. Thrombosis and Haemostasis2014;112(4):640‐8. [PUBMED: 24696161] ">van der Poll 2014</a>). </p> <p>Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic intravascular activation of coagulation, leading to deposition of fibrin in the bloodstream, which occurs in the course of several diseases (<a href="./references#CD008562-bbs2-0068" title="DalainasI . Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review. European Review for Medical and Pharmacological Sciences2008;12(1):19‐31. [PUBMED: 18401969] ">Dalainas 2008</a>; <a href="./references#CD008562-bbs2-0078" title="FranchiniM , LippiG , ManzatoF . Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thrombosis Journal2006;4:4. [PUBMED: 16504043] ">Franchini 2006</a>; <a href="./references#CD008562-bbs2-0111" title="LeviM , van derPollT . Disseminated intravascular coagulation: a review for the internist. Internal and Emergency Medicine2013;8(1):23‐32. [PUBMED: 23015284] ">Levi 2013</a>). It has been considered as a loss of homeostasis in hemostasis (<a href="./references#CD008562-bbs2-0093" title="HookKM , AbramsCS . The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients. Clinical and Translational Science2012;5(1):85‐92. [PUBMED: 22376264] ">Hook 2012</a>). </p> <p>The morbidity of DIC is related to organ dysfunction and bleeding, which explains the high risk of death associated with this harmful and potentially fatal condition (<a href="./references#CD008562-bbs2-0108" title="LeviM . Disseminated intravascular coagulation. Critical Care Medicine2007;35(9):2191‐5. [PUBMED: 17855836] ">Levi 2007</a>). Organ dysfunction is explained by intravascular fibrin deposition (ischemic phase); the microvascular thromboses lead to organ damage and failure (<a href="./references#CD008562-bbs2-0064" title="ChuAJ . Biochemical strategies to anticoagulation: a comparative overview. Current Vascular Pharmacology2004;2(3):199‐228. [PUBMED: 15320820] ">Chu 2004</a>; <a href="./references#CD008562-bbs2-0134" title="WadaH , MatsumotoT , YamashitaY , HatadaT . Disseminated intravascular coagulation: testing and diagnosis. Clinica Chimica Acta2014;436:130‐4. [PUBMED: 24792730] ">Wada 2014</a>; <a href="./references#CD008562-bbs2-0135" title="WilliamsJ , MozurkewichE , ChilimigrasJ , Van DeVenC . Critical care in obstetrics: pregnancy‐specific conditions. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2008;22(5):825‐46. [PUBMED: 18775679] ">Williams 2008</a>). The bleeding phase is due to massive and ongoing activation of bloodstream coagulation, which leads to depletion of platelets and activated coagulation factors (<a href="./references#CD008562-bbs2-0068" title="DalainasI . Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review. European Review for Medical and Pharmacological Sciences2008;12(1):19‐31. [PUBMED: 18401969] ">Dalainas 2008</a>; <a href="./references#CD008562-bbs2-0078" title="FranchiniM , LippiG , ManzatoF . Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thrombosis Journal2006;4:4. [PUBMED: 16504043] ">Franchini 2006</a>). This explains why DIC is also known as consumption coagulopathy (<a href="./references#CD008562-bbs2-0111" title="LeviM , van derPollT . Disseminated intravascular coagulation: a review for the internist. Internal and Emergency Medicine2013;8(1):23‐32. [PUBMED: 23015284] ">Levi 2013</a>). It has been suggested that DIC represents up to 26.8% of acquired bleeding disorders (<a href="./references#CD008562-bbs2-0056" title="AsthanaB , SharmaP , RanjanR , JainP , AravindanA , Chandra MishraP , et al. Patterns of acquired bleeding disorders in a tertiary care hospital. Clinical and Applied Thrombosis/Hemostasis2009;15(4):448‐53. [PUBMED: 19520680] ">Asthana 2009</a>). However, it has a poorly established incidence and a heterogeneous clinical presentation. <a href="./references#CD008562-bbs2-0115" title="OkajimaK , SakamotoY , UchibaM . Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. American Journal of Hematology2000;65(3):215‐22. [PUBMED: 11074538] ">Okajima 2000</a> described a 12.7% incidence of DIC induced by hematologic malignancies in 204 patients with other underlying disorders. In summary, DIC is an acquired clotting catastrophe (<a href="./references#CD008562-bbs2-0069" title="DeLougheryTG . Critical care clotting catastrophies. Critical Care Clinics2005;21(3):531‐62. [PUBMED: 15992672] ">DeLoughery 2005</a>) that cannot be considered an isolated clinical entity and it should be managed as a hematological emergency. </p> <p>DIC is one of the major complications of acute myeloid leukemia (<a href="./references#CD008562-bbs2-0059" title="BunjevackiG , SultanY , IzraëlV . [Disseminated intravascular coagulation (D.I.C.) and fibrinolysis in patients with acute leukemia (author's transl)] [Coagulation intravasculaire disséminée et fibrinolyse au cours des leucemies aiguës]. Nouvelle Revue Française d'Hématologie1978;20(4):575‐84. [PUBMED: 752151] ">Bunjevacki 1978</a>; <a href="./references#CD008562-bbs2-0071" title="DmoszyńskaA . Intravascular disseminated coagulation syndrome in patients with acute leukemias [Zespol rozsianego krzepniecia srodnaczyniowego u chorych na ostre bialaczki]. Acta Haematologica Polonica1976;7(2):139‐46. [PUBMED: 1065178] ">Dmoszyńska 1976</a>), mainly promyelocytic leukemia (<a href="./references#CD008562-bbs2-0057" title="BarbuiT , FalangaA . Disseminated intravascular coagulation in acute leukemia. Seminars in Thrombosis and Hemostasis2001;27(6):593‐604. [PUBMED: 11740683] ">Barbui 2001</a>; <a href="./references#CD008562-bbs2-0063" title="ChoudhryA , DeLougheryTG . Bleeding and thrombosis in acute promyelocytic leukemia. American Journal of Hematology2012;87(6):596‐603. [PUBMED: 22549696] ">Choudhry 2012</a>; <a href="./references#CD008562-bbs2-0067" title="CornellRF , PalmerJ . Adult acute leukemia. Disease‐a‐Month2012;58(4):219‐38. [PUBMED: 22449370] ">Cornell 2012</a>; <a href="./references#CD008562-bbs2-0074" title="DreyfusB , VaretB , Heilmann‐GouaultM , SultanC , ReyesF , GluckmanE , et al. The treatment of disseminated intravascular coagulation in 18 cases of promyelocytic acute leukaemia (author's translation) [Traitement dans 18 observations de leucémies aiguës promyélocytaires de la coagulation intravasculaire disséminée]. Nouvelle Revue Française d'Hématologie1973;13(6):761‐70. [PUBMED: 4280042] ">Dreyfus 1973</a>; <a href="./references#CD008562-bbs2-0107" title="KwaanHC . The unique hemostatic dysfunction in acute promyelocytic leukemia. Seminars in Thrombosis and Hemostasis2014;40(3):332‐6. [PUBMED: 24590422] ">Kwaan 2014</a>; <a href="./references#CD008562-bbs2-0112" title="Lo‐CocoF , AmmatunaE , MontesinosP , SanzMA . Acute promyelocytic leukemia: recent advances in diagnosis and management. Seminars in Oncology2008;35(4):401‐9. [PUBMED: 18692690] ">Lo‐Coco 2008</a>; <a href="./references#CD008562-bbs2-0126" title="SpeiserW , Pabinger‐FaschingI , KyrlePA , KapiotisS , Kottas‐HeldenbergA , BettelheimP , et al. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis. Blut1990;61(5):298‐302. [PUBMED: 2271776] ">Speiser 1990</a>; <a href="./references#CD008562-bbs2-0127" title="SteinE , McMahonB , KwaanH , AltmanJK , FrankfurtO , TallmanMS . The coagulopathy of acute promyelocytic leukaemia revisited. Best Practice &amp; Research. Clinical Haematology2009;22(1):153‐63. [PUBMED: 19285282] ">Stein 2009</a>; <a href="./references#CD008562-bbs2-0131" title="UchiumiH , MatsushimaT , YamaneA , DokiN , IrisawaH , SaitohT , et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. International Journal of Hematology2007;86(2):137‐42. [PUBMED: 17875527] ">Uchiumi 2007</a>; <a href="./references#CD008562-bbs2-0136" title="YanadaM , MatsushitaT , SuzukiM , KiyoiH , YamamotoK , KinoshitaT , et al. Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation. European Journal of Haematology2006;77(4):282‐7. [PUBMED: 16856920] ">Yanada 2006</a>). However, it can also complicate the clinical course of acute lymphoblastic leukemia (<a href="./references#CD008562-bbs2-0070" title="DixitA , ChatterjeeT , MishraP , KannanM , ChoudhryDR , MahapatraM , et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clinical and Applied Thrombosis/Hemostasis2007;13(3):292‐8. [PUBMED: 17636191] ">Dixit 2007</a>; <a href="./references#CD008562-bbs2-0075" title="Durán SuárezJR , Juncá PieraJ , Zuazu NagoreJ , Triginer BoixedaJM . Disseminated intravascular coagulation as the presenting feature of lymphoblastic leukemia. Study of a case [Coagulación intravascular diseminada como forma de presentación de leucosis linfoblástica. Estudio de un caso]. Medicina Clínica1980;75(9):391‐3. [PUBMED: 6936572] ">Durán Suárez 1980</a>; <a href="./references#CD008562-bbs2-0090" title="HiguchiT , ToyamaD , HirotaY , IsoyamaK , MoriH , NiikuraH , et al. Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: a study of childhood and adult cases. Leukemia &amp; Lymphoma2005;46(8):1169‐76. [PUBMED: 16085558] ">Higuchi 2005</a>; <a href="./references#CD008562-bbs2-0122" title="SarrisAH , KempinS , BermanE , MichaeliJ , LittleC , AndreeffM , et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood1992;79(5):1305‐10. [PUBMED: 1536954] ">Sarris 1992</a>), chronic myeloid leukemia (<a href="./references#CD008562-bbs2-0080" title="FujiwaraH , TakahashiN , TadaJ , HiguchiT , HaradaH , MoriH , et al. Blast crisis accompanied by severe DIC of Ph negative chronic myeloid leukemia showing t(9;16) and positive M‐BCR/ABL rearrangement [Japanese]. Rinsho Ketsueki1997;38(8):663‐8. [PUBMED: 9311272] ">Fujiwara 1997</a>; <a href="./references#CD008562-bbs2-0081" title="García de ParedesML , González LarribaJL , Ordoñez GallegoA , Martínez MartínezB , Montero GarcíaJM . Disseminated intravascular coagulation as the 1st manifestation of a chronic myeloid leukemia [Spanish]. Medicina Clínica (Barc)1983;81(8):369‐70. [PUBMED: 6580521] ">García de Paredes 1983</a>; <a href="./references#CD008562-bbs2-0082" title="GermanHJ , SmithJA , LindenbaumJ . Chronic intravascular coagulation associated with chronic myelocytic leukemia. Use of heparin in connection with a surgical procedure. American Journal of Medicine1976;61(4):547‐52. [PUBMED: 1067753] ">German 1976</a>; <a href="./references#CD008562-bbs2-0083" title="GingrichRD , BurnsCP . Disseminated coagulopathy in chronic myelomonocytic leukemia. Cancer1979;44(6):2249‐53. [PUBMED: 292510] ">Gingrich 1979</a>; <a href="./references#CD008562-bbs2-0087" title="HessEP , SztajnkrycerMD . Images in emergency medicine. Acute leukemia with blast crisis, disseminated intravascular coagulation, and intraparenchymal hemorrhage. Annals of Emergency Medicine2005;46(4):314, 322. [PUBMED: 16187462] ">Hess 2005</a>; <a href="./references#CD008562-bbs2-0106" title="KomatsuN , YoshidaN , TsuboyamaA , SatoY , SakamotoS , MiuraY . Promyelocytic crisis of chronic myelogenous leukemia: coagulopathy similar to atypical disseminated intravascular coagulation in acute promyelocytic leukemia. Nippon Ketsueki Gakkai Zasshi1986;49(4):894‐9. [PUBMED: 3464156] ">Komatsu 1986</a>; <a href="./references#CD008562-bbs2-0121" title="RosenthalNS , KnappD , FarhiDC . Promyelocytic blast crisis of chronic myelogenous leukemia. A rare subtype associated with disseminated intravascular coagulation. American Journal of Clinical Pathology1995;103(2):185‐8. [PUBMED: 7856560] ">Rosenthal 1995</a>; <a href="./references#CD008562-bbs2-0125" title="SeligmanBR , RosnerF , SolomonRB . Chronic myelogenous leukemia. Disseminated intravascular coagulation and chloromas containing sea‐blue histiocytes. New York State Journal of Medicine1975;75(8):1271‐4. [PUBMED: 1055903] ">Seligman 1976</a>; <a href="./references#CD008562-bbs2-0128" title="Sunder‐PlassmannG , SpeiserW , KorningerC , StainM , BettelheimP , Pabinger‐FaschingI , et al. Disseminated intravascular coagulation and decrease in fibrinogen levels induced by vincristine/prednisolone therapy of lymphoid blast crisis of chronic myeloid leukemia. Annals of Hematology1991;62(5):169‐73. [PUBMED: 2049463] ">Sunder‐Plassmann 1993</a>; <a href="./references#CD008562-bbs2-0137" title="YoshikawaH , MaruoK . Blastic crisis of a chronic myelogenous leukemia with disseminated intravascular coagulation, with special reference to &quot;AAAP&quot; therapy (author's translation) [Japanese]. Rinsho Ketsueki [Japanese Journal of Clinical Hematology]1980;21(1):52‐8. [PUBMED: 6929365] ">Yoshikawa 1980</a>) and chronic lymphocytic leukemia (<a href="./references#CD008562-bbs2-0023" title="KawanoN , KuriyamaT , YoshidaS , YamashitaK , OchiaiH , NakazakiS , et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Internal Medicine2013;52(1):55‐62. [PUBMED: 23291674] KawanoN , TasakiA , KuriyamaT , TaharaY , YoshidaS , OnoN , et al. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution‐‐an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases. Internal Medicine2014;53(3):205‐13. [PUBMED: 24492688] KawanoN , YoshidaS , OnoN , HimejiD , NagahiroY , SayakaK , et al. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution. Journal of Clinical and Experimental Hematopathology2011;51(2):101‐7. [PUBMED: 22104308] ">Kawano 2011</a>). DIC in leukemia is accompanied by hyperfibrinolysis and reduction of natural anticoagulants (protein C and antithrombin III) (<a href="./references#CD008562-bbs2-0063" title="ChoudhryA , DeLougheryTG . Bleeding and thrombosis in acute promyelocytic leukemia. American Journal of Hematology2012;87(6):596‐603. [PUBMED: 22549696] ">Choudhry 2012</a>; <a href="./references#CD008562-bbs2-0079" title="FranchiniM , DiMinnoMN , CoppolaA . Disseminated intravascular coagulation in hematologic malignancies. Seminars in Thrombosis and Hemostasis2010;36(4):388‐403. [PUBMED: 20614391] ">Franchini 2010</a>; <a href="./references#CD008562-bbs2-0096" title="HuntBJ . Bleeding and coagulopathies in critical care. New England Journal of Medicine2014;370(9):847‐59. [PUBMED: 24571757] ">Hunt 2014</a>; <a href="./references#CD008562-bbs2-0021" title="IkezoeT , TakeuchiA , IsakaM , ArakawaY , IwabuN , KinT , et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leukemia Research2012;36(11):1398‐402. [PUBMED: 22917769] ">Ikezoe 2012</a>; <a href="./references#CD008562-bbs2-0107" title="KwaanHC . The unique hemostatic dysfunction in acute promyelocytic leukemia. Seminars in Thrombosis and Hemostasis2014;40(3):332‐6. [PUBMED: 24590422] ">Kwaan 2014</a>). The main feature of this condition is the enhanced generation of thrombin in vivo (<a href="./references#CD008562-bbs2-0110" title="LeviM , TohCH , ThachilJ , WatsonHG . Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology2009;145(1):24‐33. [PUBMED: 19222477] ">Levi 2009</a>). </p> <p>The pathogenesis of DIC is based on tissue‐factor‐mediated initiation of systemic coagulation that is insufficiently contained by the physiological anticoagulant pathways, and is amplified by impaired endogenous fibrinolysis (<a href="./references#CD008562-bbs2-0077" title="FalangaA , RicklesFR . Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Practice &amp; Research. Clinical Haematology2003;16(3):463‐82. [PUBMED: 12935963] ">Falanga 2003</a>; <a href="./references#CD008562-bbs2-0079" title="FranchiniM , DiMinnoMN , CoppolaA . Disseminated intravascular coagulation in hematologic malignancies. Seminars in Thrombosis and Hemostasis2010;36(4):388‐403. [PUBMED: 20614391] ">Franchini 2010</a>; <a href="./references#CD008562-bbs2-0099" title="IkezoeT . Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. International Journal of Hematology2014;100(1):27‐37. [PUBMED: 24217998] ">Ikezoe 2014</a>; <a href="./references#CD008562-bbs2-0108" title="LeviM . Disseminated intravascular coagulation. Critical Care Medicine2007;35(9):2191‐5. [PUBMED: 17855836] ">Levi 2007</a>; <a href="./references#CD008562-bbs2-0127" title="SteinE , McMahonB , KwaanH , AltmanJK , FrankfurtO , TallmanMS . The coagulopathy of acute promyelocytic leukaemia revisited. Best Practice &amp; Research. Clinical Haematology2009;22(1):153‐63. [PUBMED: 19285282] ">Stein 2009</a>; <a href="./references#CD008562-bbs2-0134" title="WadaH , MatsumotoT , YamashitaY , HatadaT . Disseminated intravascular coagulation: testing and diagnosis. Clinica Chimica Acta2014;436:130‐4. [PUBMED: 24792730] ">Wada 2014</a>). The clinical entity is propagated by intravascular release of procoagulant substances, such as tissue thromboplastin, or by damage to vascular endothelium and platelets (<a href="./references#CD008562-bbs2-0119" title="PrenticeCR . Acquired coagulation disorders. Clinics in Haematology1985;14(2):413‐42. [PUBMED: 3899441] ">Prentice 1985</a>).<br/> <br/> Guidelines for the diagnosis of DIC have recently been published (<a href="./references#CD008562-bbs2-0110" title="LeviM , TohCH , ThachilJ , WatsonHG . Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology2009;145(1):24‐33. [PUBMED: 19222477] ">Levi 2009</a>). <a href="#CD008562-tbl-0005">Table 1</a> shows the International Society of Thrombosis and Haemostasis scoring system for overt DIC. </p> <div class="table" id="CD008562-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic scoring system for DIC (Levi 2009)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Scoring system for overt DIC,</b> </p> <p><b>International Society of Thrombosis and Haemostasis (ISHT) </b>( <a href="./references#CD008562-bbs2-0110" title="LeviM , TohCH , ThachilJ , WatsonHG . Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology2009;145(1):24‐33. [PUBMED: 19222477] ">Levi 2009</a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A) Risk assessment</b> </p> <p>Does the patient have any underlying disorder known<br/> to be associated with overt DIC? </p> <p>If yes: proceed</p> <p>If no: do not use this algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>B) Order global coagulation tests</b> <br/> (prothrombin time, platelet count, fibrinogen,<br/> fibrin‐related marker) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>C) Score the test results</b> </p> <p><i>Platelet count:</i> <br/> &gt; 100 x 10<sup>9</sup>/L = 0<br/> &lt; 100 x 10<sup>9</sup>/L = 1<br/> &lt; 50 x 10<sup>9</sup>/L = 2 </p> <p><i>Elevated fibrin marker:</i> <br/> (D‐dimer, fibrin degradation products)<br/> (no increase = 0, moderate increase = 2,<br/> strong increase = 3) </p> <p><i>Prolonged PT:</i> <br/> (&lt; 3 s = 0; &gt; 3 but &lt; 6 s = 1; &gt; 6 s = 2) </p> <p>Fibrinogen level (&gt; 1 g/L = 0; &lt; 1 g/L =1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>D) Calculate score</b> </p> <p>≥ 5 compatible with overt DIC: repeat score daily</p> <p>&lt; 5 suggestive for non‐overt DIC: repeat next 1 to 2 days</p> </td> </tr> </tbody> </table> </div> <p>See <a href="./appendices#CD008562-sec-0106">Appendix 1</a> for medical terms. </p> </section> <section id="CD008562-sec-0018"> <h3 class="title" id="CD008562-sec-0018">Description of the intervention</h3> <p>Treatment of the underlying disease must be the cornerstone of therapy (<a href="./references#CD008562-bbs2-0068" title="DalainasI . Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review. European Review for Medical and Pharmacological Sciences2008;12(1):19‐31. [PUBMED: 18401969] ">Dalainas 2008</a>; <a href="./references#CD008562-bbs2-0108" title="LeviM . Disseminated intravascular coagulation. Critical Care Medicine2007;35(9):2191‐5. [PUBMED: 17855836] ">Levi 2007</a>; <a href="./references#CD008562-bbs2-0119" title="PrenticeCR . Acquired coagulation disorders. Clinics in Haematology1985;14(2):413‐42. [PUBMED: 3899441] ">Prentice 1985</a>). Additionally supportive anticoagulant approaches have been used with the aim of resolving coagulation abnormalities. The drugs used include the following: </p> <p> <ol id="CD008562-list-0001"> <li> <p>First‐generation anticoagulants: low molecular weight heparin (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>; <a href="./references#CD008562-bbs2-0097" title="IbaT , NagaokaI , BoulatM . The anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation. Thrombosis Research2013;131(5):383‐9. [PUBMED: 23566533] ">Iba 2013</a>), unfractionated heparin (<a href="./references#CD008562-bbs2-0095" title="HoyleCF , SwirskyDM , FreedmanL , HayhoeFG . Beneficial effect of heparin in the management of patients with APL. British Journal of Haematology1988;68(3):283‐9. [PUBMED: 3162683] ">Hoyle 1988</a>; <a href="./references#CD008562-bbs2-0113" title="MangalAK , GrossmanL , VickarsL . Disseminated intravascular coagulation in acute monoblastic leukemia: response to heparin therapy. Canadian Medical Association Journal1984;130(6):731‐3. [PUBMED: 6582992] ">Mangal 1984</a>) and danaparoid sodium (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>; <a href="./references#CD008562-bbs2-0097" title="IbaT , NagaokaI , BoulatM . The anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation. Thrombosis Research2013;131(5):383‐9. [PUBMED: 23566533] ">Iba 2013</a>); </p> </li> <li> <p>Second‐generation anticoagulants: synthetic protease inhibitor (<a href="./references#CD008562-bbs2-0130" title="TsukagoshiS . Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation [Japanese]. Gan to Kagaku Ryoho. Cancer and Chemotherapy2000;27(5):767‐74. [PUBMED: 10832450] ">Tsukagoshi 2000</a>), recombinant hirudin (<a href="./references#CD008562-bbs2-0037" title="SaitoM , AsakuraH , JokajiH , UotaniC , KumabashiriI , MorishitaE , et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. Blood Coagulation &amp; Fibrinolysis1995;6(1):60‐4. [PUBMED: 7540878] ">Saito 1995</a>), human recombinant antithrombin (<a href="./references#CD008562-bbs2-0097" title="IbaT , NagaokaI , BoulatM . The anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation. Thrombosis Research2013;131(5):383‐9. [PUBMED: 23566533] ">Iba 2013</a>; <a href="./references#CD008562-bbs2-0116" title="PalN , KertaiMD , LakshminarasimhacharA , AvidanMS . Pharmacology and clinical applications of human recombinant antithrombin. Expert Opinion on Biological Therapy2010;10(7):1155‐68. [PUBMED: 20528611] ">Pal 2010</a>), human recombinant activated protein C (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>; <a href="./references#CD008562-bbs2-0097" title="IbaT , NagaokaI , BoulatM . The anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation. Thrombosis Research2013;131(5):383‐9. [PUBMED: 23566533] ">Iba 2013</a>), recombinant human soluble thrombomodulin (<a href="./references#CD008562-bbs2-0097" title="IbaT , NagaokaI , BoulatM . The anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation. Thrombosis Research2013;131(5):383‐9. [PUBMED: 23566533] ">Iba 2013</a>; <a href="./references#CD008562-bbs2-0021" title="IkezoeT , TakeuchiA , IsakaM , ArakawaY , IwabuN , KinT , et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leukemia Research2012;36(11):1398‐402. [PUBMED: 22917769] ">Ikezoe 2012</a>; <a href="./references#CD008562-bbs2-0032" title="OgawaE , YagasakiH , KatoM , ShichinoH , ChinM , MugishimaH . Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin. British Journal of Haematology2010;149(6):911‐2. [PUBMED: 20346017] ">Ogawa 2010</a>) and recombinant tissue factor pathway inhibitor (<a href="./references#CD008562-bbs2-0103" title="KaiserB , HoppensteadtDA , FareedJ . Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs2001;10(11):1925‐35. [PUBMED: 11772296] ">Kaiser 2001</a>); </p> </li> <li> <p>Antifibrinolytic drugs: tranexamic acid (<a href="./references#CD008562-bbs2-0110" title="LeviM , TohCH , ThachilJ , WatsonHG . Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology2009;145(1):24‐33. [PUBMED: 19222477] ">Levi 2009</a>; <a href="./references#CD008562-bbs2-0133" title="WadaH , AsakuraH , OkamotoK , IbaT , UchiyamaT , KawasugiK , et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thrombosis Research2010;125(1):6‐11. [PUBMED: 19782389] ">Wada 2010</a>). The use of a combination of tranexamic acid and unfractionated heparin has also been reported (<a href="./references#CD008562-bbs2-0024" title="KosekiM , AsadaN , UryuH , TakeuchiM , AsakuraH , MatsueK . Successful combined use of tranexamic acid and unfractionated heparin for life‐threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. International Journal of Hematology2007;86(5):403‐6. [PUBMED: 18192107] ">Koseki 2007</a>); </p> </li> <li> <p>Pro‐coagulants: recombinant activated factor VIIa (<a href="./references#CD008562-bbs2-0055" title="AbshireT , KenetG . Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. Journal of Thrombosis and Haemostasis2004;2(6):899‐909. [PUBMED: 15140125] ">Abshire 2004</a>). </p> </li> </ol> </p> </section> <section id="CD008562-sec-0019"> <h3 class="title" id="CD008562-sec-0019">How the intervention might work</h3> <p>The aim of anticoagulant drugs is to fulfil the role of the natural anticoagulants (protein C and antithrombin systems) which are disrupted during DIC. A close relationship between coagulation and inflammation pathways during DIC has also been identified: "inflammation leads to activation of coagulation and coagulation considerably affects inflammatory activity" (<a href="./references#CD008562-bbs2-0109" title="LeviM , van derPollT . The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Seminars in Thrombosis and Hemostasis2008;34(5):459‐68. [PUBMED: 18956286] ">Levi 2008</a>). </p> <p>1. First generation anticoagulants catalyze the inhibition of several coagulation proteases by antithrombin (a natural anticoagulant) which inhibits activated coagulation factors of the intrinsic and common pathways, including thrombin, factors Xa and IXa. Heparin increases the rate of the thrombin‐antithrombin reaction by at least 1000‐fold (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>). Danaparoid sodium is a mixture of non‐heparin glycosaminoglycans isolated from porcine intestinal mucosa (84% heparan sulfate, 12% dermatan sulfate, 4% chondroitin sulfate) and responsible for promoting inhibition of factor Xa by antithrombin (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>). </p> <p>2. Second‐generation anticoagulants:<br/> 2.1 Synthetic protease inhibitor is a protease inhibitor with anticoagulant properties (<a href="./references#CD008562-bbs2-0130" title="TsukagoshiS . Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation [Japanese]. Gan to Kagaku Ryoho. Cancer and Chemotherapy2000;27(5):767‐74. [PUBMED: 10832450] ">Tsukagoshi 2000</a>);<br/> 2.2 Recombinant hirudin is an anticoagulant pharmacodynamically different from heparin (<a href="./references#CD008562-bbs2-0085" title="GreinacherA , LubenowN . Recombinant hirudin in clinical practice. Circulation2001;103(10):1479‐84. [PUBMED: 11245656] ">Greinacher 2001</a>) and a product of genetic engineering. It is identical to natural hirudin. It is a direct thrombin inhibitor present in the salivary glands of the medicinal leech (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>; <a href="./references#CD008562-bbs2-0085" title="GreinacherA , LubenowN . Recombinant hirudin in clinical practice. Circulation2001;103(10):1479‐84. [PUBMED: 11245656] ">Greinacher 2001</a>; <a href="./references#CD008562-bbs2-0114" title="NowakG . Pharmacology of recombinant hirudin. Seminars in Thrombosis and Hemostasis2002;28(5):415‐24. [PUBMED: 12420236] ">Nowak 2002</a>);<br/> 2.3 Recombinant human soluble thrombomodulin has an antithrombotic effect (reducing coagulation) by neutralizing the effect of thrombin (<a href="./references#CD008562-bbs2-0021" title="IkezoeT , TakeuchiA , IsakaM , ArakawaY , IwabuN , KinT , et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leukemia Research2012;36(11):1398‐402. [PUBMED: 22917769] ">Ikezoe 2012</a>);<br/> 2.4 Recombinant tissue factor pathway inhibitor is the only endogenous inhibitor of the tissue factor/factor VIIa complex that plays a crucial role in the pathogenesis of thrombotic, vascular and inflammatory disorders (<a href="./references#CD008562-bbs2-0103" title="KaiserB , HoppensteadtDA , FareedJ . Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs2001;10(11):1925‐35. [PUBMED: 11772296] ">Kaiser 2001</a>);<br/> 2.5 Human recombinant activated protein C is a recombinant form of human activated protein C that inhibits coagulation by proteolytic inactivation of factors Va and VIIIa. It also has anti‐inflammatory effects (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>). </p> <p>3. Antifibrinolytic drugs (aminocaproic acid and tranexamic acid) inhibit the conversion to plasminogen and plasmin, blocking the interaction of plasmin with fibrin. This leads to a potent inhibition of fibrinolysis and can reverse states that are associated with excessive fibrinolysis (<a href="./references#CD008562-bbs2-0058" title="BruntonL , ParkerK , BlumenthalD , BuxtonI . Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: BruntonL , ParkerK , BlumenthalD , BuxtonI editor(s). Goodman &amp; Gilman's Manual of Pharmacology and Therapeutics. 11th Edition. New York: McGraw‐Hill Companies, Inc, 2008:949‐66. [DOI: 10.1036/0071443436] ">Brunton 2008</a>); </p> <p>4. Pro‐coagulant drugs (recombinant activated factor VIIa) bind to the surface of an activated platelet and can directly activate factor X in the absence of tissue factor (<a href="./references#CD008562-bbs2-0055" title="AbshireT , KenetG . Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. Journal of Thrombosis and Haemostasis2004;2(6):899‐909. [PUBMED: 15140125] ">Abshire 2004</a>). </p> </section> <section id="CD008562-sec-0020"> <h3 class="title" id="CD008562-sec-0020">Why it is important to do this review</h3> <p>This is the first update of this Cochrane Review, which we performed to update the search strategy (May 2015) to identify new randomized controlled trials (RCTs) on pharmacological interventions to treat DIC in patients with acute and chronic leukemia. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008562-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008562-sec-0021"></div> <p>The research question of this Cochrane Review is: what are the clinical benefits and harms of anticoagulant and antifibrinolytic therapy for treating DIC in patients with acute or chronic leukemia? </p> <p>To assess the clinical benefits and harms of pharmacological interventions for treating DIC in patients with acute or chronic leukemia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008562-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008562-sec-0022"></div> <section id="CD008562-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008562-sec-0024"> <h4 class="title">Types of studies</h4> <p>RCTs irrespective of publication status (unpublished or published as an article, an abstract or a letter), language (no language limitation was applied) and country of origin. We did not apply any limits on the period of follow‐up or diagnostic criteria used for DIC. </p> </section> <section id="CD008562-sec-0025"> <h4 class="title">Types of participants</h4> <p>Patients of any age with DIC and suffering from acute or chronic leukemia.</p> </section> <section id="CD008562-sec-0026"> <h4 class="title">Types of interventions</h4> <p>DIC requires resolution of the underlying condition in addition to other approaches, such as antibiotic therapy, replacement of blood products and fluid therapy, which are considered 'primary' or 'conventional care' interventions. Anticoagulant, procoagulant and antifibrinolytic drugs are considered complementary to the conventional care interventions. Thus, for the purposes of this Cochrane Review, eligible RCTs had to compare the same conventional interventions with and without anticoagulants, with and without procoagulants, or with and without antifibrinolytics. </p> <section id="CD008562-sec-0027"> <h5 class="title">Intervention</h5> <p> <ol id="CD008562-list-0002"> <li> <p>Heparins (low molecular weight heparin and unfractionated heparin);</p> </li> <li> <p>Danaparoid sodium;</p> </li> <li> <p>Antifibrinolytic drugs (epsilon aminocaproic and tranexamic acid);</p> </li> <li> <p>Synthetic protease inhibitor and antithrombin;</p> </li> <li> <p>Human recombinant activated protein C;</p> </li> <li> <p>Recombinant human soluble thrombomodulin;</p> </li> <li> <p>Recombinant tissue factor pathway inhibitor;</p> </li> <li> <p>Recombinant activated factor VIIa;</p> </li> <li> <p>and Recombinant hirudin and antifibrinolytic drugs.</p> </li> </ol> </p> <p>plus resolution of the underlying condition, conventional care (antibiotic therapy, replacement of blood products, fluid therapy). </p> </section> <section id="CD008562-sec-0028"> <h5 class="title">Control</h5> <p>Resolution of the underlying condition with conventional care (antibiotic therapy, replacement of blood products, fluid therapy) alone or plus placebo. </p> </section> </section> <section id="CD008562-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD008562-sec-0030"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008562-list-0003"> <li> <p>Overall mortality (<a href="./references#CD008562-bbs2-0118" title="PortaM . A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008. ">Porta 2008</a>); </p> </li> <li> <p>In‐hospital mortality from any cause (15‐day and 30‐day);</p> </li> <li> <p>Adverse events: number and type of adverse events defined as patients with any untoward medical occurrence not necessarily having a causal relationship with the treatment. We reported adverse events that led to treatment discontinuation and those that did not lead to treatment discontinuation separately. We have defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<a href="./references#CD008562-bbs2-0098" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR &amp; ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>) as any event that at any dose results in death, is life‐threatening, requires in‐patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, or is a congenital anomaly/birth defect, and any important medical event, which may have jeopardized the patient or requires intervention to prevent it. All other adverse events were considered non‐serious. </p> </li> </ol> </p> </section> <section id="CD008562-sec-0031"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008562-list-0004"> <li> <p>Bleeding;</p> </li> <li> <p>Resolution of respiratory failure;</p> </li> <li> <p>Resolution of renal failure;</p> </li> <li> <p>Resolution of shock (defined as the condition associated with circulatory collapse, when the arterial blood pressure is too low to maintain an adequate supply of blood to the tissues) (<a href="./references#CD008562-bbs2-0066" title="MartinE . Concise Medical Dictionary. 8th Edition. New York: Oxford University Press, 2011. ">Concise Medical Dictionary 2011</a>). </p> </li> </ol> </p> </section> </section> </section> <section id="CD008562-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <p>The MEDLINE search strategy used in the first version of this Cochrane Review was not very sensitive (<a href="./references#CD008562-bbs2-0139" title="Marti‐CarvajalAJ , SimancasD , CardonaAF . Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2] ">Marti‐Carvajal 2011</a>) and could have generated publication bias. Therefore, we performed this review update using a new MEDLINE search strategy. </p> <section id="CD008562-sec-0033"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to find reports of relevant RCTs:</p> <p> <ul id="CD008562-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2015, Issue 05); </p> </li> <li> <p>MEDLINE OVID (1946 to 7 May 2015);</p> </li> <li> <p>LILACS (<a href="http://lilacs.bvsalud.org/es/" target="_blank">http://lilacs.bvsalud.org/es/</a>): 1982 to 7 May 2015: </p> </li> <li> <p>African Index Medicus (<a href="http://indexmedicus.afro.who.int/" target="_blank">http://indexmedicus.afro.who.int/</a>): 7 May 2015: </p> </li> </ul> </p> <p>In the previous review version, we also searched EMBASE (<a href="./references#CD008562-bbs2-0139" title="Marti‐CarvajalAJ , SimancasD , CardonaAF . Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2] ">Marti‐Carvajal 2011</a>). For this update, we did not search the EMBASE database. </p> <p>We used the following keywords in our search: DIC, consumption coagulopathy, acute leukemia and chronic leukemia. </p> </section> <section id="CD008562-sec-0034"> <h4 class="title">Searching other resources</h4> <p>In addition we searched trials registries via the World Health Organization International Clinical Trials Platform Search Portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">WHO ICTRP</a>). </p> <p>We also checked the reference lists of all trials identified by the above methods. We contacted trial authors and researchers in the field to obtain further details about unpublished studies. </p> </section> </section> <section id="CD008562-sec-0035"> <h3 class="title" id="CD008562-sec-0035">Data collection and analysis</h3> <section id="CD008562-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors (Arturo Martí‐Carvajal (AMC) and Vidhu Anand (VA)) independently assessed for inclusion all the potential studies identified from the search strategy. We resolved any disagreements through discussion. </p> </section> <section id="CD008562-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>In the previous version of this Cochrane Review (<a href="./references#CD008562-bbs2-0139" title="Marti‐CarvajalAJ , SimancasD , CardonaAF . Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2] ">Marti‐Carvajal 2011</a>), we used a form to extract data (<a href="./references#CD008562-bbs2-0138" title="ZavalaD , Martí‐CarvajalA , Peña‐MartíG , ComuniánG . Data extraction sheet to help manage the characteristics of included studies in Cochrane reviews. Valencia, Venezuela: Universidad de Carabobo, 2006. ">Zavala 2006</a>). For assessing the eligible studies, two review authors (AMC and VA) extracted the data independently using the agreed form. We entered data into <a href="./references#CD008562-bbs2-0120" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> and checked them for accuracy. We resolved discrepancies through discussion or, if required, we consulted a third review author (Ivan Solà (IS)). </p> <p>For this update, if we had included new RCTs, we would have used the same strategy.</p> </section> <section id="CD008562-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias (AMC and VA) of each included trial using the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008562-bbs2-0089" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved discrepancies through discussion or, if necessary , we consulted a third author (IS). </p> <p>The definitions of each classification is given below:</p> <section id="CD008562-sec-0039"> <h5 class="title">Sequence generation (checking for possible selection bias)</h5> <p> <ul id="CD008562-list-0006"> <li> <p>Low risk (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>High risk (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>Unclear (if the trial was described as randomized, but the method used for the allocation sequence generation was not described).    </p> </li> </ul> </p> </section> <section id="CD008562-sec-0040"> <h5 class="title">Allocation concealment (checking for possible selection bias)</h5> <p> <ul id="CD008562-list-0007"> <li> <p>Low risk (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>High risk (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>Unclear risk (if the trial was described as randomized, but the method used to conceal the allocation was not described). </p> </li> </ul> </p> </section> <section id="CD008562-sec-0041"> <h5 class="title">Blinding or masking (checking for possible performance bias)</h5> <p> <ul id="CD008562-list-0008"> <li> <p>Low, high or unclear risk for participants;</p> </li> <li> <p>Low, high or unclear risk for personnel;</p> </li> <li> <p>Low risk, high or unclear risk for outcome assessors.</p> </li> </ul> </p> </section> <section id="CD008562-sec-0042"> <h5 class="title">Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations) </h5> <p> <ul id="CD008562-list-0009"> <li> <p>Low risk (the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals); </p> </li> <li> <p>High risk (the number or reasons for dropouts and withdrawals were not described);</p> </li> <li> <p>Unclear risk (the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated)./// </p> </li> </ul> </p> </section> <section id="CD008562-sec-0043"> <h5 class="title">Selective reporting bias</h5> <p> <ul id="CD008562-list-0010"> <li> <p>Low risk (where it is clear that all of the trial's pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>High risk (where not all the trial's pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; trial fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>Unclear risk (not all pre‐defined, or clinically relevant and reasonably expected outcomes were reported on, or were not reported fully, or it was unclear whether data on these outcomes were recorded or not). </p> </li> </ul> </p> </section> <section id="CD008562-sec-0044"> <h5 class="title">Other biases</h5> <p>We described for each included RCT any important concerns we had about other possible sources of bias (industry bias, academic bias, bias of the presentation data, etc.): </p> <p> <ul id="CD008562-list-0011"> <li> <p>Low risk (the trial appears to be free of other components that could put it at risk of bias); </p> </li> <li> <p>High risk (there are other factors in the trial that could put it at risk of bias);</p> </li> <li> <p>Unclear risk (the trial may or may not be free of other components that could put it at risk of bias). </p> </li> </ul> </p> </section> <section id="CD008562-sec-0045"> <h5 class="title">Overall risk of bias</h5> <p>We considered trials in which we could assess one of the domains as high risk of bias as trials with high risk of bias. </p> <p>We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in <a href="./references#CD008562-bbs2-0089" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>. </p> <p>In the previous version (<a href="./references#CD008562-bbs2-0139" title="Marti‐CarvajalAJ , SimancasD , CardonaAF . Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2] ">Marti‐Carvajal 2011</a>), AMC entered the data into <a href="./references#CD008562-bbs2-0120" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> and a second review author checked data for accuracy. In this current version, AMC entered the data into <a href="./references#CD008562-bbs2-0120" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> and IS checked data for accuracy. </p> </section> </section> <section id="CD008562-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we planned to present results as a summary risk ratio (RR) with 95% confidence intervals (CIs). </p> <p> <ol id="CD008562-list-0012"> <li> <p>Mortality from any cause (15‐day and 30‐day in‐hospital);</p> </li> <li> <p>Adverse events;</p> </li> <li> <p>Bleeding;</p> </li> <li> <p>Resolution of respiratory failure;</p> </li> <li> <p>Resolution of renal failure;</p> </li> <li> <p>Resolution of shock.</p> </li> </ol> </p> </section> <section id="CD008562-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis would have been the patients studied. We would have collected and analyzed a single measurement for each outcome from each participant. </p> </section> <section id="CD008562-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We planned to note levels of attrition and explore the impact of high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes we would have carried out analysis, as far as possible, on an intention‐to‐treat basis (i.e. we would have attempted to include all participants randomized to each group in the analyses). The denominator for each outcome in each trial would have been the number randomized minus any participants whose outcomes are known to be missing. </p> <p>For future updates, if possible, we will conduct main analysis based on completers but we will perform sensitivity analysis for per‐protocol, worse and best case scenarios (<a href="./references#CD008562-bbs2-0092" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999;319(7211):670‐4. [PUBMED: 10480822] ">Hollis 1999</a>). </p> </section> <section id="CD008562-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to use the I² statistic to measure statistical heterogeneity among the trials in each analysis. In the presence of substantial heterogeneity we would have explored this by pre‐specified subgroup analysis. The I² statistic describes the percentage of total variation across trials that is due to heterogeneity rather than sampling error (<a href="./references#CD008562-bbs2-0088" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [PUBMED: 12958120] ">Higgins 2003</a>). We would have considered a substantial statistical heterogeneity if the I² statistic was greater than 50% (<a href="./references#CD008562-bbs2-0089" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD008562-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had suspected reporting bias (see 'Selective reporting bias' section), we would have attempted to contact the trial authors asking them to provide missing outcome data. When this was not possible, and the missing data were thought to introduce serious bias, we would have explored the impact of including such studies in the overall assessment of results by a sensitivity analysis.  </p> <p>We would also have attempted to assess whether the review is subject to publication bias by using a funnel plot to graphically illustrate variability between trials. If asymmetry was detected, we would have explored causes other than publication bias (e.g. selective outcome reporting, poor methodological quality in smaller studies, true heterogeneity) (<a href="./references#CD008562-bbs2-0089" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). In future updates we will construct a funnel plot if 10 or more RCTs meet the inclusion criteria. </p> </section> <section id="CD008562-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We planned to out statistical analyses using <a href="./references#CD008562-bbs2-0120" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> and summarize the findings using a random‐effects model, as differences would have been anticipated in terms of interventions and patients. </p> </section> <section id="CD008562-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We anticipated clinical heterogeneity for the following participant and intervention characteristics, and therefore we would have carried out the following subgroup analyses: </p> <p> <ol id="CD008562-list-0013"> <li> <p>Acute versus chronic leukemia;</p> </li> <li> <p>Type of intervention;</p> </li> <li> <p>Stage of DIC; and</p> </li> <li> <p>Unfractionated heparin dose.</p> </li> </ol> </p> <p>We would have restricted subgroup analysis to the review’s primary outcome (<a href="./references#CD008562-bbs2-0089" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD008562-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>If sufficient trials are identified, we plan to conduct a sensitivity analysis comparing the results using all trials. We would have compared the RCTs with high methodological quality (studies classified as having a 'low risk of bias' versus those identified as having a 'high risk of bias') (<a href="./references#CD008562-bbs2-0089" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We would also have evaluated the risk of attrition bias, as estimated by the percentage of participants lost. We would have excluded trials with a total attrition of more than 20% or where differences between the groups exceeded 10%, or both, from meta‐analysis but would have included them in the review. </p> <section id="CD008562-sec-0054"> <h5 class="title">'Summary of findings' tables</h5> <p>We planned to use The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD008562-bbs2-0086" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , and GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>) to assess the quality of the body of evidence associated with specific outcomes (mortality from any cause (15‐day and 30‐day in‐hospital), overall mortality, bleeding, resolution of respiratory failure, renal failure or shock and adverse events) in this Cochrane Review and construct a 'Summary of findings' table using <a href="./references#CD008562-bbs2-0084" title="BrozekJ , OxmanA , SchünemannH . Grading of Recommendations Assessment, Development and Evaluation (GRADE). Version 3.2. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, 2008. ">GRADEpro 2008</a>. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within‐trial risk of bias (methodologic quality), the directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008562-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008562-sec-0055"></div> <section id="CD008562-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD008562-sec-0057"> <h4 class="title">Results of the search</h4> <p>For this update, we identified 9027 references of potential interest after duplicates were removed. We did not find any new eligible RCTs. Therefore, this Cochrane Review update includes the four RCTs identified in the original review version (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). See <a href="#CD008562-fig-0001">Figure 1</a> for search result details. </p> <div class="figure" id="CD008562-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for this review update." data-id="CD008562-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for this review update.</p> </div> </div> </div> <p>These RCTs included 388 participants for analysis. We have provided a detailed description of the included trials in the <a href="./references#CD008562-sec-0122" title="">Characteristics of included studies</a> section. </p> </section> <section id="CD008562-sec-0058"> <h4 class="title">Included studies</h4> <p>We classified the included trials as:</p> <p> <ol id="CD008562-list-0014"> <li> <p>Including patients with or without leukemia (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>); </p> </li> <li> <p>Only including patients with leukemia (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> </li> </ol> </p> <p>Two trials were conducted in 1989 (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>;) and 1994 (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>) and the other two trials were conducted during 2002 (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>) and 2007 (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). </p> <section id="CD008562-sec-0059"> <h5 class="title">Interventions and populations assessed</h5> <p>Each trial investigated a different intervention to treat DIC: human activated protein C (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>), recombinant human soluble thrombomodulin (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>), tranexamic acid (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>) and dermatan sulphate (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). All included trials had a parallel‐trial design and compared two arms. The route of administration of the intervention was intravenous in all trials. </p> <p>Three trials used heparin as comparison group (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007;</a><a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). One trial used placebo (glucose 5% (w/v) in 10 mL sterile water) (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>). </p> <p>Two trials had a follow‐up length under 20 days, ranging between nine and 18 days (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). Two trials had a follow‐up length of 28 days (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> <p>One trial with 132 patients included many types of leukemia, solid tumors, infection and other causes (liver diseases and aortic aneurysm) of DIC. Patients were classified in two groups: leukemic (hematopoietic malignancy and anti‐cancer chemotherapy) and non‐leukemic (infection and other causes such as liver disease and aortic aneurysm) (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>). One trial reported results from 234 patients including acute or chronic leukemia, another hematopoietic malignancies, sepsis, pneumonia, biliary tract infection, peritonitis, abscess, viremia, meningitis, cholangitis, enterocolitis and other infections (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). Two trials were only conducted in patients with leukemia (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> included 12 patients with newly diagnosed acute promyelocytic leukemia. <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> considered ten patients with many types of acute leukemia and those who had a blast crisis due to chronic myelogenous leukemia. </p> <p>Overall, included participants were above 50 years of age and most were male.</p> </section> <section id="CD008562-sec-0060"> <h5 class="title">Trial location</h5> <p>The included trials were conducted in three countries: two in Japan (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>), one trial in Italy (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>) and one trial was conducted in Italy and the Netherlands (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>). </p> </section> <section id="CD008562-sec-0061"> <h5 class="title">Trial methods</h5> <p>Two trials were reported as phase‐III (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>), two trials did not report the trial phase (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). Two trials were multicenter (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>) and the site was unclear in two trials (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). All trials were conducted using a parallel group trial design. Three trials were conducted without reporting an a priori sample size estimation (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). Two trials were designed to include few leukemic patients (fewer than 15 cases): 12 and 10 participants in <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> and <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>, respectively. The trials including other causes of DIC were conducted with sample sizes of between 55 and 104 participants (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). Two trials did not describe their exclusion criteria (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). One trial is associated with a duplicate publication (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> </section> </section> <section id="CD008562-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 50 studies for the following reasons: 10 were case reports (<a href="./references#CD008562-bbs2-0007" title="Aviles de la GarzaR , Perez TamayoR , Becker FauseI , Linares PontonG , Anaya GalindoR . Intravascular disseminated coagulation. Critical analysis of a 5 years experience at the Instituto Nacional de la Nutrición Salvador Zubirán (Mexico) [Coagulación intravascular diseminada. Análisis crítico de la experiencia del Instituto Nacional de la Nutricion Salvador Zubirán en 5 años]. Revista de Investigación Clínica1982;34(4):307‐12. [13075 (LILACS)] ">Aviles de la Garza 1982</a>; <a href="./references#CD008562-bbs2-0024" title="KosekiM , AsadaN , UryuH , TakeuchiM , AsakuraH , MatsueK . Successful combined use of tranexamic acid and unfractionated heparin for life‐threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. International Journal of Hematology2007;86(5):403‐6. [PUBMED: 18192107] ">Koseki 2007</a>; <a href="./references#CD008562-bbs2-0027" title="Martínez LópezI , Jiménez ArmadaJ , Ballmajó RealM , Sánchez GarcíaRW , Solano RolandoM . Fulminant disseminated intravascular coagulation in a patient with acute promyelocytic leukaemia [Coagulación intravascular diseminada fulminante en una paciente con leucemia promielocítica aguda]. Revista Cubana de Medicina2002;4(1):303‐7. [354369 (LILACS)] ">Martínez López 2002</a>; <a href="./references#CD008562-bbs2-0032" title="OgawaE , YagasakiH , KatoM , ShichinoH , ChinM , MugishimaH . Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin. British Journal of Haematology2010;149(6):911‐2. [PUBMED: 20346017] ">Ogawa 2010</a>; <a href="./references#CD008562-bbs2-0034" title="PizzutoJ , Gonzalez LlavenJ , Uribe CortesJA . Heparin as treatment for hypercoagulability syndrome in a case of acute promyelocytic leukemia [Spanish]. Sangre1969;14(3):363‐70. [PUBMED: 5288844] ">Pizzuto 1969</a>; <a href="./references#CD008562-bbs2-0039" title="SandlerRM , LiebmanHA , PatchMJ , TeitelbaumA , LevineAM , FeinsteinDI . Antithrombin III and anti‐activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin. Cancer1982;50(10):2106‐10. [PUBMED: 6957257] SandlerRM , LiebmanHA , PatchMJ , TeitelbaumA , LevineAM , FeinsteinDI . Antithrombin III and anti‐activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin. Cancer1983;51(4):681‐5. [PUBMED: 6571800] ">Sandler 1982</a>; <a href="./references#CD008562-bbs2-0041" title="ShindoM , IkutaK , AddoL , ItoS , FujiyaM , TorimotoY , et al. Successful control of disseminated intravascular coagulation by recombinant thrombomodulin during arsenic trioxide treatment in relapsed patient with acute promyelocytic leukemia. Case Reports in Hematology2012;2012:908196. [PUBMED: 23008787] ">Shindo 2012</a>; <a href="./references#CD008562-bbs2-0044" title="SugawaraT , OkudaM , YamaguchiY , EndoK , YoshinagaK . Successful treatment with tranexamic acid for severe bleeding in acute promyelocytic leukemia. Acta Haematologica1992;87(1‐2):109. [PUBMED: 1585765] ">Sugawara 1992</a>; <a href="./references#CD008562-bbs2-0045" title="TakagiK , TasakiT , YamauchiT , IwasakiH , UedaT . Successful administration of recombinant human soluble thrombomodulin (Recomodulin) for disseminated intravascular coagulation during induction chemotherapy in an elderly patient with acute monoblastic leukemia involving the t(9;11)(p22;q23) MLL/AF9 translocation. Case Reports in Hematology2011;2011:273070. [PUBMED: 22937304] ">Takagi 2011</a>; <a href="./references#CD008562-bbs2-0051" title="YamaguchiM , MurataR , MizutaniT , KawamuraY , UedaM . Acute myelogenous leukemia associated with disseminated intravascular coagulation and acute myocardial infarction at relapse [Japanese]. Rinsho Ketsueki (Japanese Journal of Clinical Haematology)2001;42(9):716‐8. [PUBMED: 11680986] ">Yagamuchi 2001</a>), seven were non‐ RCTs (<a href="./references#CD008562-bbs2-0018" title="HoffmannJN , MühlbayerD , JochumM , InthornD . Effect of long‐term and high‐dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Critical Care Medicine2004;32(9):1851‐9. [PUBMED: 15343012] ">Hoffmann 2004</a>; <a href="./references#CD008562-bbs2-0020" title="IbaT , SaitoD , WadaH , AsakuraH . Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thrombosis Research2012;130(3):e129‐33. [PUBMED: 22542365] ">Iba 2012</a>; <a href="./references#CD008562-bbs2-0021" title="IkezoeT , TakeuchiA , IsakaM , ArakawaY , IwabuN , KinT , et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leukemia Research2012;36(11):1398‐402. [PUBMED: 22917769] ">Ikezoe 2012</a>; <a href="./references#CD008562-bbs2-0038" title="SakuragawaN , HasegawaH , MakiM , NakagawaM , NakashimaM . Clinical evaluation of low molecular weight heparin (FR‐860) on disseminated intravascular coagulation (DIC): a multicenter cooperative double‐blind trial in comparison with heparin. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1992;8(2):423‐52. SakuragawaN , HasegawaH , MakiM , NakagawaM , NakashimaM . Clinical evaluation of low‐molecular‐weight heparin (FR‐860) on disseminated intravascular coagulation (DIC) ‐ a multicenter co‐operative double‐blind trial in comparison with heparin. Thrombosis Research1993;72(6):475‐500. [PUBMED: 8128454] ">Sakuragawa 1992</a>; <a href="./references#CD008562-bbs2-0046" title="TakezakoN , SekiguchiN , NotoS , OginoY , MiwaA , IkezoeT . Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: Results of a multicenter, retrospective epidemiologic study in Japan. Blood. 2014; Vol. 124:2875. [CN‐01049686] ">Takezako 2014</a>; <a href="./references#CD008562-bbs2-0049" title="WadaH , WakitaY , NakaseT , ShimuraM , HiyoyamaK , NagayaS , et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thrombosis and Haemostasis1995;74(3):848‐52. [PUBMED: 8571309] ">Wada 1995</a>; <a href="./references#CD008562-bbs2-0052" title="YamatoM , MinematsuY , FujiiJ , MoriK , MinatoT , MiyagawaS , et al. Effective combination therapy of polymyxin‐B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial. Therapeutic Apheresis and Dialysis2013;17(5):472‐6. [PUBMED: 24107274] ">Yamato 2013</a>), 11 were case series (<a href="./references#CD008562-bbs2-0011" title="GambaG , GrignaniG , BiancardiM , GeroldiD , AscariE . Acute leukemias and D.I.C.: effectiveness of treatment with low doses of heparin. Haematologica1979;64(3):322‐30. [PUBMED: 113300] ">Gamba 1979</a>; <a href="./references#CD008562-bbs2-0013" title="GillisS , DannEJ , EldorA . Low molecular weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute promyelocytic leukemia. European Journal of Hematology1995;54(1):59‐60. [PUBMED: 7859878] ">Gillis 1995</a>; <a href="./references#CD008562-bbs2-0014" title="GralnickHR , BagleyJ , AbrellE . Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia. American Journal of Medicine1972;52(2):167‐74. [PUBMED: 4500954] ">Glarnick 1972</a>; <a href="./references#CD008562-bbs2-0016" title="GoldbergMA , GinsburgD , MayerRJ , StoneRM , MaguireM , RosenthalDS , et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?. Blood1987;69(1):187‐91. [PUBMED: 3466655] ">Goldberg 1987</a>; <a href="./references#CD008562-bbs2-0029" title="NieuwenhuisHK , SixmaJJ . Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer1986;58(3):761‐4. [PUBMED: 2425925] ">Nieuwenhuis 1986</a>; <a href="./references#CD008562-bbs2-0031" title="NowrousianMR , HilgardP . Low‐dose heparin in the management of acute myelocytic leukaemia. Blut1978;37(6):341‐3. [PUBMED: 281971] ">Nowrousian 1978</a>; <a href="./references#CD008562-bbs2-0035" title="PoglianiEM , SalvatoreM , MaseraG , CorneoG . Antifibrinolytic therapy in acute promyelocytic leukemia. Acta Haematologica1989;81(1):58‐9. [PUBMED: 2494837] ">Pogliani 1989</a>; <a href="./references#CD008562-bbs2-0036" title="Rodríguez GómezM , López FernándezMF , BatlleJ . Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases [Terapéutica de la coagulación intravascular diseminada en las leucemias agudas promielocíticas. A propósito de 19 casos]. Sangre1993;38(6):449‐53. [PUBMED: 8171380] ">Rodríguez Gómez 1993</a>; <a href="./references#CD008562-bbs2-0037" title="SaitoM , AsakuraH , JokajiH , UotaniC , KumabashiriI , MorishitaE , et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. Blood Coagulation &amp; Fibrinolysis1995;6(1):60‐4. [PUBMED: 7540878] ">Saito 1995</a>; <a href="./references#CD008562-bbs2-0042" title="ShirahataA , MimuroJ , TakahashiH , KitajimaI , TsujiH , EguchiY , et al. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation. European Journal of Pediatrics2014;173(3):303‐11. [PUBMED: 24005342] ">Shirahata 2014</a>; <a href="./references#CD008562-bbs2-0047" title="VinazzerH . Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Seminars in Thrombosis and Hemostasis1989;15(3):347‐52. [PUBMED: 2688106] ">Vinazzer 1989</a>), seven were observational studies (<a href="./references#CD008562-bbs2-0005" title="AokiN , HirosawaS , KurosawaS , MatsudaT , SaitoH , TakamatsuJ , et al. Clinical evaluation of low molecular weight heparin preparation (LHN‐1) on disseminated intravascular coagulation (DIC): multicenter phase II clinical study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1994;10(12):2629‐65. ">Aoki 1994</a>; <a href="./references#CD008562-bbs2-0022" title="KatoT , SakaiT , KatoM , HagiharaM , HasegawaT , MatsuuraK , et al. Recombinant human soluble thrombomodulin administration improves sepsis‐induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thrombosis Journal2013;11(1):3. [PUBMED: 23414216] ">Kato 2013</a>; <a href="./references#CD008562-bbs2-0023" title="KawanoN , KuriyamaT , YoshidaS , YamashitaK , OchiaiH , NakazakiS , et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Internal Medicine2013;52(1):55‐62. [PUBMED: 23291674] KawanoN , TasakiA , KuriyamaT , TaharaY , YoshidaS , OnoN , et al. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution‐‐an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases. Internal Medicine2014;53(3):205‐13. [PUBMED: 24492688] KawanoN , YoshidaS , OnoN , HimejiD , NagahiroY , SayakaK , et al. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution. Journal of Clinical and Experimental Hematopathology2011;51(2):101‐7. [PUBMED: 22104308] ">Kawano 2011</a>; <a href="./references#CD008562-bbs2-0028" title="MatsushitaT , WatanabeJ , HondaG , MimuroJ , TakahashiH , TsujiH , et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open‐label, multicenter, post‐marketing surveillance study cohort. Thrombosis Research2014;133(5):772‐81. [PUBMED: 24636871] ">Matsushita 2014</a>; <a href="./references#CD008562-bbs2-0040" title="SawamuraA , GandoS , HayakawaM , HoshinoH , KubotaN , SuganoM . Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clinical and Applied Thrombosis/Hemostasis2009;15(5):561‐6. [PUBMED: 18840625] ">Sawamura 2009</a>; <a href="./references#CD008562-bbs2-0053" title="YangH , ZhuCY , WangQS , NiuJH , ZhangQ , ZhuHY , et al. Analysis of empirical treatment for newly diagnosed acute promyelocytic leukemia combined with disseminated intravascular coagulation [Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi/Zhongguo Bing li Sheng li Xue hui/Journal of Experimental Hematology/Chinese Association of Pathophysiology2014;22(2):315‐22. [PUBMED: 24762998] ">Yang 2014</a>; <a href="./references#CD008562-bbs2-0054" title="YinQ , LiC . Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation. Evidence‐based Complementary and Alternative Medicine2014;2014:949254. [PUBMED: 24778706] ">Yin 2014</a>), one was a systematic review (<a href="./references#CD008562-bbs2-0010" title="FranchiniM , ManzatoF , SalvagnoGL , LippiG . Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagulation &amp; Fibrinolysis2007;18(7):589‐93. [PUBMED: 17890943] ">Franchini 2007</a>), one was a narrative review (<a href="./references#CD008562-bbs2-0050" title="WaliaSS , WaliaHS . Therapeutic interventions in endotoxin‐induced disseminated intravascular coagulation. Journal of Natural Science, Biology, and Medicine2012;3(1):108‐9. [PUBMED: 22690065] ">Walia 2012</a>), five were RCTs excluding patients with leukemia (<a href="./references#CD008562-bbs2-0009" title="FourrierF , ChopinC , HuartJ J , RungeI , CaronC , GoudemandJ . Double‐blind, placebo‐controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest1993;104(3):882‐8. [PUBMED: 8365305] ">Fourrier 1993</a>; <a href="./references#CD008562-bbs2-0012" title="GandoS , SaitohD , IshikuraH , UeyamaM , OtomoY , OdaS , et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care2013;17(6):R297. [PUBMED: 24342495] ">Gando 2013</a>; <a href="./references#CD008562-bbs2-0019" title="HofmannM , RestA , HafnerG , TannerB , BrockerhoffP , WeilemannLS . Evaluation of coagulation and fibrinolytics parameters in the therapeutic management of disseminated intravascular coagulation with sepsis by low molecular weight/heparin [German]. Der Anaesthesist1997;46(8):689‐96. [PUBMED: 9382207] ">Hofmann 1997</a>; <a href="./references#CD008562-bbs2-0030" title="NishiyamaT , KohnoY , KoishiK . Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. American Journal of Emergency Medicine2012;30(7):1219‐23. [PUBMED: 22204993] ">Nishiyama 2012</a>; <a href="./references#CD008562-bbs2-0043" title="ShpilbergO , BlumenthalR , SoferO , EldorA , Ben BassatI . A controlled trial of tranexamic acid (TA) treatment for reduction of bleeding during acute myeloid leukemia (AML) induction and consolidation. Blood1993;82(10 Suppl 1):547a. [CN‐00461734] ShpilbergO , BlumenthalR , SoferO , KatzY , ChetritA , RamotB , et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leukemia &amp; Lymphoma1995;19(1‐2):141‐4. [PUBMED: 8574160] ">Shpilberg 1995</a>), one was a RCT for preventing DIC in leukemia (<a href="./references#CD008562-bbs2-0008" title="ChojnowskiK , TrelinskiJ , WawrzyniakE , RobakT . The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy‐‐report of a prospective randomized study. Leukemia &amp; Lymphoma2002;43(5):1021‐8. [PUBMED: 12148881] ">Chojnowski 2002</a>) and seven were excluded for miscellaneous reasons (<a href="./references#CD008562-bbs2-0006" title="AsakuraH , TakahashiH , TsujiH , MatsushitaT , NinomiyaH , HondaG , et al. Post‐marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation ‐ safety and efficacy in 1,032 patients with hematologic malignancy. Thrombosis Research2014;133(3):364‐70. ">Asakura 2014</a>; <a href="./references#CD008562-bbs2-0015" title="GöbelU , vonVossH , JurgensH , PetrichC , PothmannR , SprockI , et al. Efficiency of heparin in the treatment of newborn infants with respiratory distress syndrome and disseminated intravascular coagulation. European Journal of Pediatrics1980;133(1):47‐9. [PUBMED: 7353570] ">Göbel 1980</a>; <a href="./references#CD008562-bbs2-0017" title="GrossSJ , FilstonHC , AndersonJC . Controlled study of treatment for disseminated intravascular coagulation in the neonate. Journal of Pediatrics1982;100(3):445‐8. [PUBMED: 7038076] ">Gross 1982</a>; <a href="./references#CD008562-bbs2-0025" title="KienastJ , JuersM , WiedermannCJ , HoffmannJN , OstermannH , StraussR , et al. Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis2006;4(1):90‐7. [PUBMED: 16409457] ">KYBERSEPT 2006</a>; <a href="./references#CD008562-bbs2-0026" title="LiuXL , WangXZ , LiuXX , HaoD , JaladatY , LuF , et al. Low‐dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Experimental and Therapeutic Medicine2014;7(3):604‐8. [PUBMED: 24520253] ">Liu 2014</a>; <a href="./references#CD008562-bbs2-0033" title="OgumaY , SakuragawaN , MakiM , HasegawaH , NakagawaM . Treatment of disseminated intravascular coagulation with low molecular weight heparin. Research Group of FR‐860 on DIC in Japan. Seminars in Thrombosis and Hemostasis1990;16 Suppl:34‐40. [PUBMED: 1962902] OgumaY , SakuragawaN , MakiM , NakagawaM , HasegawaH . Clinical effect of low molecular weight heparin (fragmin) on DIC: a multicenter cooperative study in Japan. Thrombosis Research1990;59(1):37‐49. [PUBMED: 2169078] ">Oguma 1990</a>; <a href="./references#CD008562-bbs2-0048" title="VincentJL , RameshMK , ErnestD , LaRosaSP , PachlJ , AikawaN , et al. A randomized, double‐blind, placebo‐controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART‐123, in patients with sepsis and suspected disseminated intravascular coagulation. Critical Care Medicine2013;41(9):2069‐79. [PUBMED: 23979365] ">Vincent 2013</a>). </p> <p>See the <a href="./references#CD008562-sec-0123" title="">Characteristics of excluded studies</a> table. </p> <section id="CD008562-sec-0063"> <h5 class="title">Ongoing trials</h5> <p>We found no ongoing RCTs.</p> </section> </section> </section> <section id="CD008562-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarized the risk of bias of the included RCTs in <a href="#CD008562-fig-0002">Figure 2</a> and <a href="#CD008562-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008562-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD008562-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD008562-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD008562-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <section id="CD008562-sec-0065"> <h4 class="title">Allocation</h4> <section id="CD008562-sec-0066"> <h5 class="title">Sequence generation</h5> <p>One RCT was rated as having low risk of bias because the trial authors used computer generation for assigning the participants (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). Three RCTs reported insufficient information to permit judgment as 'low risk' or 'high risk'. Therefore, we rated them at unclear risk of bias (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> </section> <section id="CD008562-sec-0067"> <h5 class="title">Allocation concealment</h5> <p>One RCT was rated as having low risk of bias (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). Three RCTs showed unclear risk of bias (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> </section> </section> <section id="CD008562-sec-0068"> <h4 class="title">Blinding</h4> <p>One trial was reported as blinded; however, it was not described how participants and personnel were blinded. Therefore, it was rated as having unclear risk of bias (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>). Three trials did not report any information about this domain; so, were rated as having unclear risk of bias (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> </section> <section id="CD008562-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> had a low risk of bias for attrition bias. <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a> lost 21.3% of patients and supplied no details of withdrawals by groups. Hence, this trial was considered as showing high risk of attrition bias. </p> </section> <section id="CD008562-sec-0070"> <h4 class="title">Selective reporting</h4> <p>Since one or more outcomes of interest were reported incompletely or not at all, <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> and <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> had high risk of reporting bias. </p> </section> <section id="CD008562-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>Insufficient information on sequence generation could have generated a potential bias of the estimated effect of exposure on an outcome due to baseline differences among exposure groups, which is known as confounding bias (<a href="./references#CD008562-bbs2-0118" title="PortaM . A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008. ">Porta 2008</a>). Therefore, <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> were rated as having a high risk of bias. </p> <p>All trials had high risk of bias due to bias in the presentation of data (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> <p>Overall, due to the limitations in the reporting of the methodology and the design for the included trials, we judged them to be at high risk of bias. </p> </section> </section> <section id="CD008562-sec-0072"> <h3 class="title" id="CD008562-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD008562-tbl-0001"><b>Summary of findings for the main comparison</b> Human activated protein C versus heparin for DIC</a>; <a href="./full#CD008562-tbl-0002"><b>Summary of findings 2</b> Recombinant human soluble thrombomodulin compared with heparin for DIC</a>; <a href="./full#CD008562-tbl-0003"><b>Summary of findings 3</b> Tranexamic acid compared with placebo for DIC</a>; <a href="./full#CD008562-tbl-0004"><b>Summary of findings 4</b> Dermatan compared with heparin for DIC</a> </p> <p>We have based the results on 356 analyzed patients out of 388 patients randomized in four included trials (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). Each trial investigated a different intervention. Two trials included patients with or without leukemia (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>) and two trials included patients with leukemia (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). We compared human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate with placebo or heparin in this review. In future updates, we will also consider any combination of these drugs (if trials were available). </p> <p>Trials including patients with or without leukemia reported effects of interventions by drugs under research rather than by disease group. Therefore, their results represent all participants in each one of these trials (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). </p> <p>None of the included trials assessed overall mortality, resolution of respiratory failure, renal failure or shock. </p> <section id="CD008562-sec-0073"> <h4 class="title">Primary outcomes  </h4> <section id="CD008562-sec-0074"> <h5 class="title">Mortality from any cause (15‐day and 30‐day in‐hospital)</h5> <section id="CD008562-sec-0075"> <h6 class="title">Trials including patients with or without leukemia</h6> <section id="CD008562-sec-0076"> <p><b>Human activated protein C versus heparin</b></p> <p>Human activated protein C notably reduced mortality from any cause compared with heparin (10/49 (20.4%) versus 22/55 (40%); RR 0.51, 95% 0.27 to 0.97; P = 0.04; <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>). </p> </section> <section id="CD008562-sec-0077"> <p><b>Recombinant human soluble thrombomodulin versus heparin</b></p> <p>There was not a significant difference in mortality from any cause between recombinant human soluble thrombomodulin versus heparin (25/114 (21.9%) versus 29/113 (25.7%); RR 0.85, 95% 0.54 to 1.36; P = 0.51; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). </p> </section> </section> <section id="CD008562-sec-0078"> <h6 class="title">Trials only conducted in patients with leukemia</h6> <section id="CD008562-sec-0079"> <p><b>Dermatan sulphate versus heparin</b></p> <p>One trial including 10 participants reported no deaths during trial treatment (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> </section> </section> </section> <section id="CD008562-sec-0080"> <h5 class="title">Adverse events</h5> <section id="CD008562-sec-0081"> <h6 class="title">Trials including patients with or without leukemia</h6> <section id="CD008562-sec-0082"> <p><b>Human activated protein C versus heparin</b></p> <p><a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a> reported a non‐significant difference between human activated protein C and heparin (1/52 (1.92%) versus 2/55 (3.63%); RR 0.53, 95% CI 0.05 to 5.66; P = 0.60). </p> </section> <section id="CD008562-sec-0083"> <p><b>Recombinant human soluble thrombomodulin versus heparin</b></p> <p>There was not a significant difference between recombinant human soluble thrombomodulin and heparin in terms of serious bleeding‐related adverse events (8/116 (6.9%) versus 9/115 (7.8%); RR 0.88, 95% CI 0.35 to 2.20; P = 0.79; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). </p> <p>Regarding non‐related bleeding serious adverse events during the 28 days, there was not a significant difference comparing recombinant human soluble thrombomodulin with heparin (37/116 (31.9%) versus 41/115 (35.6%); RR 0.89, 95% CI 0.62 to 1.28; P = 0.55; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). </p> </section> </section> <section id="CD008562-sec-0084"> <h6 class="title">Trials only conducted in patients with leukemia</h6> <section id="CD008562-sec-0085"> <p><b>Tranexamic acid versus placebo</b></p> <p><a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> did not report any thromboembolic complications in tranexamic acid or placebo group. </p> </section> <section id="CD008562-sec-0086"> <p><b>Dermatan sulphate versus heparin</b></p> <p><a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> did not report information on safety explicitly, however, the trial authors stated that among the patients without hemorraghic diathesis at trial entry, two in the heparin group and one in the dermatan sulphate developed moderate cutaneous bleeding (petechiae, ecchymoses) shortly after the start of anticoagulant treatment and none of the patients had clinically apparent thromboembolic complications. </p> </section> </section> </section> </section> <section id="CD008562-sec-0087"> <h4 class="title">Secondary outcomes  </h4> <section id="CD008562-sec-0088"> <h5 class="title">Bleeding</h5> <section id="CD008562-sec-0089"> <h6 class="title">Trials including patients with or without leukemia</h6> <section id="CD008562-sec-0090"> <p><b>Human activated protein C versus heparin</b></p> <p><a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a> compared human activated protein C versus heparin and did not find a significant difference in terms of aggravation of bleeding (0/63 (0%) versus 8/69 (11.6%); RR 0.06, 95% CI 0.00 to 1.09; P = 0.06). Regarding amelioration of bleeding, <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a> did not report any significant difference between APC and heparin (35% (22/63) versus 22% (15/69); RR 1.61, 95% CI 0.92 to 2.81; P = 0.10). </p> </section> <section id="CD008562-sec-0091"> <p><b>Recombinant human soluble thrombomodulin versus heparin</b></p> <p><a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a> reported the disappearance rate of bleeding symptoms at day seven regarding underlying disease (hematologic malignancy versus infection). Trial authors reported the clinical course of bleeding symptoms in the thrombomodulin group at day seven, which was significantly improved when compared with the heparin group (P = 0.0271). </p> </section> </section> <section id="CD008562-sec-0092"> <h6 class="title">Trials only conducted in patients with leukemia</h6> <section id="CD008562-sec-0093"> <p><b>Tranexamic acid versus placebo</b></p> <p><a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> reported this outcome using a cumulative hemorrhagic score which was composed by three items: skin bleeding, mucosal bleeding and hematuria. During the first trial period (days two to seven), it was two points for patients receiving tranexamic acid versus 31 points for control group patients (P = 0.032). During second period (days 8 to 14) of this trial, the cumulative hemorraghic scores were one point for tranexamic group and 11 points for control group (P = 0.0015). See <a href="./references#CD008562-sec-0122" title="">Characteristics of included studies</a> for cumulative hemorrhagic score details. </p> </section> <section id="CD008562-sec-0094"> <p><b>Dermatan sulphate versus heparin</b></p> <p><a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> reported a non‐significant difference between dermatan sulphate and heparin regarding moderate cutaneous bleeding (petechiae, ecchymoses) shortly after the start of anticoagulant treatment (1/5 (20%) versus 2/5 (40%); RR 0.50, 95% CI 0.06 to 3.91; P = 0.51). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008562-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008562-sec-0095"></div> <section id="CD008562-sec-0096"> <h3 class="title" id="CD008562-sec-0096">Summary of main results</h3> <p>In this updated Cochrane Review we found no new RCTs. Hence, the summary of main results comes from the first review version (<a href="./references#CD008562-bbs2-0139" title="Marti‐CarvajalAJ , SimancasD , CardonaAF . Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2] ">Marti‐Carvajal 2011</a>). </p> <p>This review of treatment for DIC in patients with acute and chronic leukemia included four RCTs (388 randomized participants, 356 analyzed) which assessed human activated protein C (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>), recombinant human soluble thrombomodulin (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>), tranexamic acid (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>) and dermatan sulphate (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). We classified these included trials as: 1) trials including patients with or without leukemia (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>); and 2) trials only including patients with leukemia (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). </p> <p> <ol id="CD008562-list-0015"> <li> <p>Trials that included patients with or without leukemia did not report data for each disease type (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>): These trials reported outcomes by drugs under research rather than by disease group. <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a> assessed symptoms, DIC score and coagulation/fibrinolysis parameters, death from any cause during treatment or within 28 days after treatment, and safety. <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a> assessed DIC resolution rate (rate of recovery from DIC) within seven days after the start of infusion (or withdrawal) (primary outcomes) and clinical course of bleeding symptoms and mortality at 28 days after the start of infusion (secondary outcomes). These trials reported safety profile of human activated protein C (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>) and recombinant human soluble thrombomodulin (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>); </p> </li> <li> <p>Trials only including patients with leukemia (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>): <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> assessed severity of bleeding, packed red cell transfusion requirements and platelet concentrate transfusion requirements. Furthermore, <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> included thromboembolic complications as safety data. <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> did not report their outcomes as primary or secondary, however they described clinically overt bleeding until hospital discharge and type and amount of daily transfusions. </p> </li> </ol> </p> <p>One trial assessing tranexamic acid versus placebo did not report information on mortality (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>). Another trial comparing dermatan sulphate versus heparin neither did not mention mortality across trial (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). In terms of bleeding data, we were unable to pool results from studies due to the inconsistency in the measurement and reporting of this outcome. <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> reported significantly reduced bleeding events with tranexamic acid compared with placebo. On the contrary, <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> found inconclusive data comparing dermatan sulphate versus heparin. Regarding adverse events, <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> reported no thromboembolic complication as adverse event. <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> did not report information on safety profile. </p> <p>The included trials did not assess overall mortality, resolution of respiratory failure, renal failure or shock as outcomes. </p> <p>Therefore it is not possible to determine whether human activated protein C (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>), recombinant human soluble thrombomodulin (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>), tranexamic acid (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>) and dermatan sulphate (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>) are effective or harmful for DIC in patients with acute and chronic leukemia. </p> </section> <section id="CD008562-sec-0097"> <h3 class="title" id="CD008562-sec-0097">Overall completeness and applicability of evidence</h3> <p>The included trials assessed two pre‐fixed primary outcomes of this review (mortality from any cause and adverse events) and one pre‐fixed secondary outcome (bleeding). There is inconsistency in reporting these outcomes. </p> <p>As mentioned above, two trials included patients with and without leukemia which did not disaggregate data by leukemia (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). It is therefore difficult to estimate the true effect of human activated protein C (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>) and recombinant human soluble thrombomodulin (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>) in patients with leukemia affected by DIC. </p> <p>All included trials had different approaches for describing the bleeding outcome: aggravation of bleeding (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>), the disappearance rate of bleeding symptoms at day seven (<a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>), hemorrhagic score (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>) and hemorrhagic diathesis (<a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). Furthermore, two trials did not assess this outcome in the leukemic group (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). </p> <p>Therefore, these important outcomes are difficult to compare, contrast or combine (<a href="./references#CD008562-bbs2-0094" title="HopewellS , ClarkeM , Higgins JPT(editors) . Core reporting of outcomes in effectiveness trials. Cochrane Methods. Cochrane Database of Systematic Reviews2010;Suppl 1:1‐29. [ISSN 2044‐4702] ">Hopewell 2010</a>). Recently, the adoption of an agreed minimum core set of outcomes for each medical condition has been suggested (<a href="./references#CD008562-bbs2-0065" title="ClarkeM . Standardising outcomes for clinical trials and systematic reviews. Trials2007;8:39. [PUBMED: 18039365] ">Clarke 2007</a>). This approach would reduce the impact of outcome reporting bias in trials (<a href="./references#CD008562-bbs2-0104" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [PUBMED: 20156912] ">Kirkham 2010</a>). See <a href="./appendices#CD008562-sec-0113">Appendix 8</a> for outcome details. </p> <p>The impact of outcome reporting bias may be reduced for adopting the recommendations of the Patient‐Centered Outcomes Research Institute (PCORI) (<a href="./references#CD008562-bbs2-0117" title='Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: "Our questions, our decisions: Standards for patient‐centered outcomes research". http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 1 April 2013):1‐61. '>PCORI 2012</a>). PCORI's research is intended to give patients a better understanding of the prevention, treatment and care options available, and the science that supports those options (<a href="./references#CD008562-bbs2-0117" title='Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: "Our questions, our decisions: Standards for patient‐centered outcomes research". http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 1 April 2013):1‐61. '>PCORI 2012</a>). </p> <p>Three trials included heparin as comparison group (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). So, we were interested in pooling data as heparin versus no‐heparin. However, we were unable to pool results from these trials due to the inconsistency in the measurement and reporting of mortality and bleeding data. <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a> and <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a> did not report data for the leukemic group. </p> <p>This update identified no new trials for reducing the uncertainty of effect of the interventions. The low number of participants carries a risk of random error (play of chance). This update shows a high risk of systematic errors (bias, that is overestimation of benefits ‐ positive false result ‐ and underestimation of harms ‐ negative false result) (<a href="./references#CD008562-bbs2-0060" title="ButtonKS , IoannidisJP , MokryszC , NosekBA , FlintJ , RobinsonES , et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews. Neuroscience2013;14(5):365‐76. [PUBMED: 23571845] ">Button 2013</a>; <a href="./references#CD008562-bbs2-0105" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [PUBMED: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD008562-bbs2-0123" title="SavovićJ , JonesH , AltmanD , HarrisR , JüniP , PildalJ . Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012</a>; <a href="./references#CD008562-bbs2-0129" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One2011;6(10):e25491. [PUBMED: 22028777] ">Thorlund 2011</a>). </p> <p>Thus, overall completeness and applicability of evidence is poor due to potential spurious findings. </p> </section> <section id="CD008562-sec-0098"> <h3 class="title" id="CD008562-sec-0098">Quality of the evidence</h3> <p>We assessed the quality of evidence as very low due to a overall high risk, and the Cochrane Review results should therefore be treated with great caution. </p> <p>The main methodological pitfalls found in the four trials included in this review were: firstly, two trials involved either patients with or without leukemia. Both type of patients were not disaggregated which limited the possibility to make conclusions about the efficacy of the treatment of patients with leukemia in this setting regarding mortality from any cause, adverse events and bleeding. One trial assessing human activated protein C, <a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>, showed unclear risk of bias for selection bias and high risk of attrition bias (21.3% loss) and the trial authors reported no reasons for attrition could bias the reported estimates. Furthermore, this trial showed imprecision due low sample size and low events which resulted in wide 95% CIs for mortality from any cause (227 participants and 54 events) and adverse events (231 participants and 17 events). <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a> showed indirectness, and imprecision due low sample size and low events which resulted in wide 95% CIs for mortality from any cause (104 participants and 32 events), adverse events (107 participants and three events) and bleeding (132 participants and eight events). Secondly, the other trials only included patients with leukemia. <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>, assessing tranexamic acid versus placebo, was rated as very low quality due to limitations in design and execution: insufficient information about random sequence generation, allocation concealment and blinding. This trial was rated as having high risk of reporting bias. Furthermore, this trial was conducted with a very small sample size (12 participants) which resulted in imprecision (i.e. wide 95% CIs). <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a> compared dermatan versus heparin showed a very low quality due to limitations in design and execution: insufficient information about random sequence generation, allocation concealment and blinding. It was conducted involving 10 participants generating imprecision in bleeding (three events) estimate. </p> <p>The quality of the evidence of safety profile was rated as very low due to indirectness in two included trials (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>) and incomplete or absent reporting of data in <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a> and <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>. </p> <p>For additional details, please, see <a href="./full#CD008562-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD008562-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008562-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008562-tbl-0004">summary of findings Table 4</a>). Our 'Risk of bias' assessment of the included trials has been described in the <a href="#CD008562-sec-0064">Risk of bias in included studies</a> section and a summary can be found in <a href="#CD008562-fig-0002">Figure 2</a> and <a href="#CD008562-fig-0003">Figure 3</a>. </p> </section> <section id="CD008562-sec-0099"> <h3 class="title" id="CD008562-sec-0099">Potential biases in the review process</h3> <p>In the process of performing a systematic review, there is a group of biases called significance‐chasing biases (<a href="./references#CD008562-bbs2-0100" title="IoannidisJP . Meta‐research: The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). This group includes publication bias, selective outcome reporting bias, selective analysis reporting bias and fabrication bias (<a href="./references#CD008562-bbs2-0100" title="IoannidisJP . Meta‐research: The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. </p> <p>Potentially, this Cochrane Review has a low risk of publication bias due to the thorough trial search process. We screened more than 8,000 studies from the year 1946. However, we include EMBASE as source in this review update. EMBASE includes more European, non‐English and drug therapy journals (<a href="./references#CD008562-bbs2-0073" title="DraperM . Which database should I use?. https://www.adelaide.edu.au/library/guide/med/wd.html (accessed 29 September 2014). ">Draper 2014</a>). </p> <p>Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to trial publication bias, in which 'negative' results remain unpublished (<a href="./references#CD008562-bbs2-0100" title="IoannidisJP . Meta‐research: The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). This Cochrane Review includes four trials with a high risk of selective outcome reporting (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>; <a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). As previously mentioned, this Cochrane Review includes two types of trials: one group including patients with or without leukemia (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>) and another group only including patients with leukemia (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). The first group did not report information by disease group (<a href="./references#CD008562-bbs2-0001" title="AokiN , MatsudaT , SaitoH , TakatsukiK , OkajimaK , TakahashiH , et al. A comparative double‐blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. International Journal of Hematology2002;75(5):540‐7. [PUBMED: 12095157] ">Aoki 2002</a>; <a href="./references#CD008562-bbs2-0002" title="AikawaN , ShimazakiS , YamamotoY , SaitoH , MaruyamaI , OhnoR , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock2011;35(4):349‐54. [PUBMED: 21068698] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation (DIC): results of phase III randomized, double‐blind, clinical trial [Abstract No. 576]. Blood2006;108(11 Part 1):174. [CN‐00624858] SaitoH , MaruyamaI , ShimazakiS , YamamotoY , AikawaN , OhnoR , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial. Journal of Thrombosis and Hemostasis2007;5(1):31‐41. [PUBMED: 17059423] ">ART‐123 Trial Group 2007</a>). We did not receive replies from the trial authors in order to get information related with leukemic group. Trial group only including patients with leukemia reported bleeding outcome with inconsistency which prevented compiling the data (<a href="./references#CD008562-bbs2-0003" title="AvvisatiG , tenCateJW , BüllerHR , MandelliF . Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet1989;2(8655):122‐4. [PUBMED: 2567893] ">Avvisati 1989</a>; <a href="./references#CD008562-bbs2-0004" title="CofrancescoE , BoschettiC , LeonardiP , CortellaroM . A randomized, heparin (H)‐controlled, pilot study of dermatan sulfate (DS) in the treatment of disseminated intravascular coagulation in acute leukemia [abstract]. Thrombosis Research1993;70(Suppl 1):74. CofrancescoE , BoschettiC , LeonardiP , CortellaroM . Dermatan sulphate in acute leukaemia. Lancet1992;339(8802):1177‐8. [PUBMED: 1349404] CofrancescoE , BoschettiC , LeonardiP , GianeseF , CortellaroM . Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukemia: a randomised, heparin‐controlled pilot study. Thrombosis Research1994;74(1):65‐75. [PUBMED: 8029809] ">Cofrancesco 1994</a>). Furthermore, none of the four included trials assessed overall mortality, resolution of respiratory failure, renal failure or shock as outcomes. </p> <p>We found two ongoing single and non‐RCTs assessing thrombomodulin for treating DIC in this population (<a href="./references#CD008562-bbs2-0102" title="YokoyamaH . Clinical study on the efficacy of recombinant thrombomodulin for DIC complicated with acute leukemia. http://www.umin.ac.jp/ctr/index.htm (accessed 29 September 2014). ">JPRN‐UMIN000008466</a>; <a href="./references#CD008562-bbs2-0101" title="TokuhiraM . Clinical efficacy of thrombomodulin alfa in hematological malignancy with disseminated intravascular coagulation. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000006738 (accessed 29 September 2014). ">JPRN‐UMIN000006738</a>). However, these trials may be useful for improving the knowledge on thrombomodulin harms but not its clinical benefit. </p> </section> <section id="CD008562-sec-0100"> <h3 class="title" id="CD008562-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>There is a strong uncertainty about the clinical benefits and harms of the interventions used for treating DIC in patients with acute or chronic leukemia. This is due to a lack of RCTs of high methodological quality. The current knowledge is based on retrospective studies (<a href="./references#CD008562-bbs2-0028" title="MatsushitaT , WatanabeJ , HondaG , MimuroJ , TakahashiH , TsujiH , et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open‐label, multicenter, post‐marketing surveillance study cohort. Thrombosis Research2014;133(5):772‐81. [PUBMED: 24636871] ">Matsushita 2014</a>; <a href="./references#CD008562-bbs2-0053" title="YangH , ZhuCY , WangQS , NiuJH , ZhangQ , ZhuHY , et al. Analysis of empirical treatment for newly diagnosed acute promyelocytic leukemia combined with disseminated intravascular coagulation [Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi/Zhongguo Bing li Sheng li Xue hui/Journal of Experimental Hematology/Chinese Association of Pathophysiology2014;22(2):315‐22. [PUBMED: 24762998] ">Yang 2014</a>) or case series (<a href="./references#CD008562-bbs2-0072" title="Dorantes‐AcostaE , Medina‐SansonA , Jaimes‐GarcíaY , López‐MartínezB . Clinical features and treatment outcomes of pediatric acute promyelocytic leukemia in a Mexican pediatric hospital. Revista de Investigación Clínica2013;65(5):392‐8. [PUBMED: 24687338] ">Dorantes‐Acosta 2013</a>; <a href="./references#CD008562-bbs2-0023" title="KawanoN , KuriyamaT , YoshidaS , YamashitaK , OchiaiH , NakazakiS , et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Internal Medicine2013;52(1):55‐62. [PUBMED: 23291674] KawanoN , TasakiA , KuriyamaT , TaharaY , YoshidaS , OnoN , et al. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution‐‐an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases. Internal Medicine2014;53(3):205‐13. [PUBMED: 24492688] KawanoN , YoshidaS , OnoN , HimejiD , NagahiroY , SayakaK , et al. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution. Journal of Clinical and Experimental Hematopathology2011;51(2):101‐7. [PUBMED: 22104308] ">Kawano 2011</a>). Therefore, this updated Cochrane Review agrees with other studies, in that there is a paucity of certainty on what is the best scientific advance for treating DIC in patients with leukemia either acute or chronic. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008562-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/urn:x-wiley:14651858:media:CD008562:CD008562-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_t/tCD008562-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for this review update." data-id="CD008562-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for this review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008562-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/urn:x-wiley:14651858:media:CD008562:CD008562-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_t/tCD008562-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD008562-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008562-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/urn:x-wiley:14651858:media:CD008562:CD008562-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_t/tCD008562-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD008562-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/media/CDSR/CD008562/image_n/nCD008562-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008562-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Human activated protein C versus heparin for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Human activated protein C versus heparin for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> human activated protein C<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Human activated protein C</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (108 to 388) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> <br/> (0.27 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (2 to 206) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.53</b> <br/> (0.05 to 5.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> <br/> (0 to 126) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.06</b> <br/> (0 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Indirectness: trial included patients with or without leukemia; and this outcome was not discriminated by type of patients.<br/> <sup>2</sup>Limitations in execution: large loss (21.3%) to follow up could bias the reported estimates. Trial authors reported no reasons for attrition could bias the reported estimates.<br/> <sup>3</sup>Imprecision: low sample size (104 participants and 32 events) resulting in wide 95% CIs.<br/> <sup>4</sup>Imprecision: low sample size (107 participants and 3 events) resulting in wide 95% CIs.<br/> <sup>5</sup>Imprecision: low sample size (132 participants and 8 events) resulting in wide 95% CIs.<br/> <sup>6</sup>Quality of evidence rated and effect estimates obtained for aggravation of bleeding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Human activated protein C versus heparin for DIC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008562-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Recombinant human soluble thrombomodulin compared with heparin for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Recombinant human soluble thrombomodulin compared with heparin for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> recombinant human soluble thrombomodulin<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Recombinant human soluble thrombomodulin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> <br/> (139 to 349) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.54 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> <br/> (27 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.35 to 2.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial did not report disaggregated data for patients with leukemia.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Indirectness: trial included patients with or without leukemia; and this outcome was not discriminated by type of patients.<br/> <sup>2</sup>Imprecision: low sample size (227 participants and 54 events) resulting in wide 95% CIs.<br/> <sup>3</sup>Imprecision: low sample size (231 participants with 17 events) resulting in wide 95% CIs.<br/> <sup>4</sup>Author trials measured this outcome either clinical benefit or harm.<br/> <sup>5</sup>Trial authors reported P = 0.0271 for "disappearance rate of bleeding symptoms at day 7". Results were not discriminated according patients with or without leukemia. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Recombinant human soluble thrombomodulin compared with heparin for DIC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008562-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tranexamic acid compared with placebo for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tranexamic acid compared with placebo for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> tranexamic acid<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported no thromboembolic events over course of trial</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 14 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial reported no number of events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included trial did not measure this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Limitations in design and execution: insufficient information about the random sequence generation, allocation concealment and blinding. High risk for reporting bias.<br/> <sup>2</sup>Imprecision: low sample size (12 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tranexamic acid compared with placebo for DIC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008562-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Dermatan compared with heparin for DIC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dermatan compared with heparin for DIC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> DIC<br/> <b>Settings:</b> acute or chronic leukemia patients<br/> <b>Intervention:</b> dermatan<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Dermatan</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from any cause (15‐day and 30‐day in‐hospital)</b> <br/> Follow‐up: 9 and 18 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial reported no death during study treatment.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: 9 and 18 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It did not report information on safety explicitly.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding</b> <br/> Follow‐up: 9 and 18 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> <b>(24 to 1000)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.5</b> <br/> <b>(0.06 to 3.91)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution of respiratory failure</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Renal failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shock</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>DIC:</b> disseminated intravascular coagulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Limitations in design and execution: insufficient information about the random sequence generation, allocation concealment, and blinding. High risk for reporting bias.<br/> <sup>2</sup>Imprecision: low sample size (10 participants) and low rate of events (3 in total) resulting in wide 95% CIs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Dermatan compared with heparin for DIC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008562-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic scoring system for DIC (Levi 2009)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Scoring system for overt DIC,</b> </p> <p><b>International Society of Thrombosis and Haemostasis (ISHT) </b>( <a href="./references#CD008562-bbs2-0110" title="LeviM , TohCH , ThachilJ , WatsonHG . Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology2009;145(1):24‐33. [PUBMED: 19222477] ">Levi 2009</a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A) Risk assessment</b> </p> <p>Does the patient have any underlying disorder known<br/> to be associated with overt DIC? </p> <p>If yes: proceed</p> <p>If no: do not use this algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>B) Order global coagulation tests</b> <br/> (prothrombin time, platelet count, fibrinogen,<br/> fibrin‐related marker) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>C) Score the test results</b> </p> <p><i>Platelet count:</i> <br/> &gt; 100 x 10<sup>9</sup>/L = 0<br/> &lt; 100 x 10<sup>9</sup>/L = 1<br/> &lt; 50 x 10<sup>9</sup>/L = 2 </p> <p><i>Elevated fibrin marker:</i> <br/> (D‐dimer, fibrin degradation products)<br/> (no increase = 0, moderate increase = 2,<br/> strong increase = 3) </p> <p><i>Prolonged PT:</i> <br/> (&lt; 3 s = 0; &gt; 3 but &lt; 6 s = 1; &gt; 6 s = 2) </p> <p>Fibrinogen level (&gt; 1 g/L = 0; &lt; 1 g/L =1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>D) Calculate score</b> </p> <p>≥ 5 compatible with overt DIC: repeat score daily</p> <p>&lt; 5 suggestive for non‐overt DIC: repeat next 1 to 2 days</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic scoring system for DIC (Levi 2009)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008562.pub3/full#CD008562-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008562.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008562-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008562-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008562-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008562\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008562\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008562\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008562\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008562\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008562.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008562.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008562.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008562.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008562.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719379156"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008562.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719379160"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008562.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de7510f90f55b',t:'MTc0MDcxOTM3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 